

---

# Sickle Cell Disease

---

## *CRITICAL ELEMENTS OF CARE*

---

*Produced by*

**The Center for Children with Special Needs  
Seattle Children's Hospital, Seattle, WA**

Fifth Edition, Revised 1/2012

---

The *Critical Elements of Care* (CEC) considers care issues across the life span of the child. The intent of the document is to educate and support those caring for a child with sickle cell disease. The CEC is intended as a general aid to health care providers to assist in the recognition of symptoms, diagnosis and care management related to a specific diagnosis. The document provides a framework for a consistent approach to management of these children.

These guidelines were developed through a consensus process. The design team was multidisciplinary with statewide representation involving primary and tertiary care providers, family members and a representative from a Health Plan.

Content reviewed and updated 1/2012:

M. A. Bender, MD, PhD

Gabrielle Seibel, MN, MPH, ARNP

This document is also available on the Center for Children with Special Needs website at [www.cshcn.org](http://www.cshcn.org).

*DISCLAIMER: Individual variations in the condition of the patient, status of patient and family, and the response to treatment, as well as other circumstances, mean that the optimal treatment outcome for some patients may be obtained from practices other than those recommended in this document. This consensus-based document is not intended to replace sound clinical judgment or individualized consultation with the responsible provider regarding patient care needs.*



My pain is the color blue.

My pain is like a crocodile biting me.  
The crocodile won't stop biting

*S.B., age 6, describing her sickle cell pain*

# TABLE OF CONTENTS

## Sickle Cell Disease CRITICAL ELEMENTS OF CARE

### I. OVERVIEW OF SICKLE CELL DISEASE

Definition of Sickle Cell Disease .....	5
Psychosocial Aspects of Sickle Cell Disease .....	5

### II. BASIC TENETS OF HEMOGLOBINOPATHY FOLLOW-UP

Hemoglobinopathy Follow-Up Program .....	8
Diagnostic Testing for the Common Sickle Cell Syndromes .....	9

### III. GUIDELINES FOR CARE OF CHILDREN WITH SICKLE CELL

Definition of Levels of Care .....	10
Clinic Requirements .....	10
Age-Specific Care Needs .....	12
Care Recommendations Tables for SS and Other Sickle Syndromes .....	18

### IV. GUIDELINES FOR PAIN MANAGEMENT

Pain Related to Sickle Cell Disease .....	25
General Principles of Pain Management .....	25
Common Pain States .....	28
Pain Assessment Tools:	
Assessment Tool 1: The Oucher .....	29
Assessment Tool 2: Pain Intensity Number Scale .....	29
Assessment Tool 3: Work Graphic Rating Scale .....	30
Assessment Tool 4: Functional Assessment.....	30
ER Management: Sickle Cell Pain Assessment .....	31
Treatment Flow Chart .....	32
Management of an Episode of Acute Pain in Sickle Cell Disease Algorithm .....	33
Complication-Specific Guidelines: Vaso-Occlusive Pain .....	35
Sedation Scale and Indications for Action.....	36
Pain Management References:	
Table 1: Research Dosage Guidelines, NSAIDS Dosing Data Table.....	37
Table 2: Research Dosage Guidelines, Opioid Dosing Data Table .....	38

**V. ALGORITHMS AND COMPLICATION SPECIFIC GUIDELINES**

Anemia Algorithm .....39  
Fever and Sepsis Algorithm.....40  
Acute Chest Syndrome .....41  
Stroke or Acute Neurologic Event .....42  
Priapism .....43  
General Anesthesia and Surgery.....44

**V. REFERENCES AND RESOURCES**

General References .....45  
Resources.....50

---

## I. OVERVIEW OF SICKLE CELL DISEASE

### Definition of Sickle Cell Disease

Sickle cell disease comprises a group of genetic disorders characterized by the inheritance of sickle hemoglobin (Hb S) from both parents, or Hb S from one parent and a gene for an abnormal hemoglobin or  $\beta$ -thalassemia from the other parent. The presence of Hb S can cause red blood cells to change from their usual biconcave disc shape to a crescent or sickle shape during de-oxygenation. Upon re-oxygenation, the red cell initially resumes a normal configuration, but after repeated cycles of “sickling and un-sickling,” the erythrocyte becomes damaged permanently and may remain sickled or may hemolyze. This hemolysis is responsible for the anemia that is the hallmark of sickle cell disease.

Acute and chronic tissue injury can occur when blood flow through the vessels is obstructed due to the abnormalities in the sickled red cells. Complications may include painful episodes involving soft tissues and bones, acute chest syndrome, priapism, cerebral vascular accidents, and both splenic and renal dysfunction. Historically, common causes of mortality among children with sickle cell disease included bacterial infections, splenic sequestration crisis and acute chest syndrome.

Sickle cell disease affects 70,000 to 100,000 Americans, primarily those of African heritage, but also those of Mediterranean, Caribbean, South and Central American, Arabian or East Indian ancestry. It is estimated that eight percent of the African American population carries the sickle cell trait, and approximately one African American child in every 375 is affected by sickle cell disease. Thus, it is the most common inherited blood disorder, and among the most prevalent of genetic diseases in the United States.

### Psychosocial Aspects of Sickle Cell Disease

Sickle cell disease is life-altering for most families. Learning to accept, cope and respond to this chronic illness requires that the practitioner and family work together. Cooperation occurs best in an environment where the family feels comfortable, safe and un-judged. The practitioner sets a tone for the relationship. That tone should encourage the family to view the practitioner as a resource, confidante and advocate.

When working with children and families affected by sickle cell disease, it is important to develop a comprehensive approach that encompasses psychosocial issues. Working to understand the issues faced by many of these families will help improve relationships and ensure a positive outcome.

### The Status of African Americans

In the U.S., sickle cell disease is primarily a disorder of African Americans. Disproportionate numbers of African Americans face economic challenges of housing, employment and daily living, and often encounter barriers to health care access. The challenge of overcoming discrimination and racism are daily realities for many families. In addition, patients and families often do not feel accepted or welcomed in many health care settings, which can significantly interfere with a child with a chronic disease receiving optimal medical care.

Although women are the head of many households, family structures vary. Raising children as a single parent is challenging – particularly in the areas of economic support, childcare and respite time for the parent. As we have become a more mobile society, single parents often face a lack of family support and experience general feelings of isolation. Extended families may include both biological family members and those who are not biologically related but who fill family roles. It is not unusual to have large numbers of “family” who care for a child and take various levels of responsibility for that child. In some cases, extended families can be overwhelming for

the parents. Parents may need support in articulating their needs in this setting and in particular, their need for privacy.

Generally, African Americans have strong spiritual beliefs that may be historical and cultural. Some families may be active participants in a church congregation and find great support or assistance from their church family. Others, while having beliefs, may not participate in any organized religious group. Still other African Americans are Muslim or Buddhist. It is important to respect these beliefs. Insensitivity or infringement upon a family's belief system can create a rift between practitioner and family.

### Effects of Physical Appearance

Children with sickle cell disease may display physical manifestations of their illness. As a result of short stature, low muscle mass or jaundiced eyes and nailbeds, ridicule by peers and others is possible. This is particularly common in children 8 to 12 years of age. Children and their parents should be prepared to use coping strategies to help them in these situations. Gaining knowledge and understanding of their illness is one such strategy. Education of schools and peers can also be helpful.

### School Attendance and Adjustment

Some children with sickle cell disease are frequently absent from school. These absences may be the result of a painful episode, hospitalization, outpatient visits and procedures or other illnesses. Frequent absences from school may result in incomplete class work and incomplete development of social skills. Students can feel disenfranchised from classroom activities and classmates.

There are a variety of responses these students may have, but the extremes of withdrawal or disruptive behavior are particularly troublesome for school personnel or families. Withdrawal may manifest in a lack of participation in classroom activities or with classmates, daydreaming, a lack of enthusiasm in the process of learning, or opposition to attending school as evidenced by verbalization or behavior. Disruptive behavior may be displayed through choices in dress or problems in interacting with other children.

These behaviors may indicate that a child is feeling overwhelmed by schoolwork, and they may not know how to ask for assistance. They may not be able to catch up on missed assignments and may not feel a sense of belonging in the classroom. This can lead to intense feelings regarding relationships at school. In most cases the child will not be able to clearly state their feelings, so they may need assistance in defining the problems. This may include testing by a neuropsychologist experienced in working with children affected by sickle cell to determine if there is an organic basis for impaired school performance. A counselor or social worker may also be helpful in working with the school system.

We encourage families to contact the school each year and to provide information about sickle cell disease to teachers, coaches, and school nurses. There may be other community professionals or resources to help families with this task. Addressing the needs of sickle cell patients, such as adequate fluid intake, frequent restroom visits, working with the child during pain episodes to decrease pain while avoiding excessive absences, and careful review of academic performance, enables the school system to become an ally of the family. School accommodations, covered by federal and state laws, should be pursued as needed.

### Physical Activities

Physical exhaustion can precipitate a painful episode in children with sickle cell disease. While it is important for children with sickle cell to participate in physical activities at school, this often occurs without the necessary supportive measures to prevent difficulties. The educational process for affected children is to ensure adequate knowledge about their disease. When affected children request fluids or petition for modified physical activity they are often seen as problem students who want special treatment. On the contrary, as children grow to understand the precipitating factors that affect their illness, the fact that they begin to advocate on their own behalf should be viewed as a positive development.

However, balancing between disease-appropriate behaviors and avoiding a negative label is difficult for children. It is imperative for parents to be involved

each year in their child’s classroom, and that they explain to teachers and administrators the special needs of their child.

As children get older, some may experience an increase in desire to compete in sports. This can result from peer or family pressure. The desire to “fit in” or “be like others” is very important for children aged 8 to 12 years. It may not be possible for some children to participate in contact sports, particularly strenuous sports, due to problems with easy fatigue or enlarged spleens. The result may be teasing by peers for not being able to participate. The child may look for other ways to prove themselves, or may participate in activities that are medically risky. At this age, children need activities that help build their self-esteem and improve understanding about their illness.

### Effects of Frequent Hospitalizations

Small children who are hospitalized should be encouraged to bring special toys, like stuffed animals to provide comfort when familiar faces are not around. Similarly, a favorite blanket or pillow can be soothing while sleeping away from home. If possible, consults with pain management teams and child life specialists can provide strategies to reduce the trauma of painful procedures (see Pain Management). This is important for children who may experience frequent and prolonged hospitalizations.

Some children require frequent hospitalizations as a result of painful episodes, infections or transfusion protocols. Long hospitalizations can cause boredom, especially if the facility does not have an orientation toward children’s activities. If a child is having problems with other children as a result of their illness, it is likely that these behaviors will continue during hospitalization.

Consulting with families about home strategies for modifying unwanted behavior should provide some support for hospital staff. Alternatively, it is important to recognize that some parents may not have adequate strategies. In this case, it is important that a child life specialist, social worker or other professional be consulted as a resource for families and staff. It is essential to assure patients have support and advocates. This can be from family, community or friends.

• Children should be encouraged to bring schoolwork to the hospital. Some facilities may have volunteers who can assist them, or paid staff members who fulfill this academic role. The school system may also provide tutors for students under certain conditions.

• Children should be encouraged to phone and text friends and family members in an effort to stay connected to life outside the hospital. These strategies allow the child to stay focused on regular activities rather than focused on their illness. Living with a chronic illness can result in a general apathy about life, which can lead to sadness or depression.

• If frequent admissions have been necessary, adolescents and their families will know the hospital system well. Many will develop expectations as to how an admission should go, and what interactions with staff will be like. In addition, they will know the flaws of the system as well, which can create tense moments for staff, patients and their families. For practitioners, it may be difficult to be confronted about staffing, equipment or the lack of communication between medical staff and families. Families may not know the best ways to communicate their concerns, so it may be necessary to help them define the problem. Some problems, like personality conflicts between specific staff members and families may not be easily remedied by the practitioner, but validating the experience and providing suggestions on how to handle situations can help reduce stress. Many hospital system problems do not have simple answers, although some families insist otherwise.

### Mortality and Sickle Cell Disease

• For families, the sickle cell diagnosis raises concerns about the affected child’s life span. It is important to talk openly about this fear with families and their children. With improvements in medical care, and parents’ involvement in learning about and teaching their children about the illness, 95% of children will live beyond age 18. The possibility of death should be addressed routinely with encouragement, emphasizing the importance of good care at home and creating a positive attitude toward life in spite of the chronic illness. Despite this, families and children should be reminded that having sickle cell should not be used as a reason to not pursue secondary education, have a career, and have a family and children.

---

## II. BASIC TENETS OF HEMOGLOBINOPATHY FOLLOW-UP

### The Basic Tenets of the Hemoglobinopathy Follow-Up Program

- Every child with sickle cell disease should have a source of primary medical care.
  - Well-child care should follow the normal guidelines of the American Academy of Pediatrics. Hematology care is not a substitute for well-child care. The primary care provider should become familiar with the Management and Therapy of Sickle Cell Diseases publication from the U.S. Department of Health and Human Services (see References on page 50).
  - A protocol for access to emergency care should be established early on.
  - Every child should have regular consultation with a physician who has expertise in the sickling disorders. Some primary physicians with special interest and skill in the sickling diseases may act both as primary physicians and consultants.
  - Children with major sickle complications (stroke, acute chest syndrome, renal or cardiac disease) should be evaluated by a tertiary care consultant familiar with treating these disorders.
  - Positive sickle hemoglobinopathy screening results should be rechecked with a second newborn screen. Confirmatory testing should then be done after 1 year of age, when Hb F levels have normalized.
  - When clinically significant hemoglobinopathies are confirmed, the primary care provider should refer to consultative care. Consultative care should be established in the first two months of life.
  - Positive sickle hemoglobinopathy screening should lead to early prophylaxis of infection and anticipatory family education about the risks to a child with a sickling disease.
- The family should have access to 24-hour-a-day medical services through the primary physician or their on-call arrangements. Sickle cell specialists and tertiary level consultation should be available 24 hours a day to physicians.
  - To ensure access to care, a social worker should be available to assist the family in identifying financial and other resources, and to connect to other state agencies.
  - Genetic counseling services should be available to all families of children with hemoglobinopathies.
  - Data on all newborn hemoglobinopathy screens should be centrally maintained so that clinicians can identify a child's hemoglobin status without rescreening.
  - Communication should be maintained between those at all levels of care.
  - Normal patterns of medical confidentiality and information exchange should be maintained.

## Diagnostic Testing for the Common Sickle Cell Syndromes

Syndrome	Phenotype	Genotype	Neonatal Screening <sup>(2)</sup>	MCV*	Hb A2 (%)* **	Hb A (%)* **	Hb S (%)* **	Hb F (%)* **	Hb C (%)* **
Sickle Cell Disease (Hb SS)	Hemolysis and anemia by age 6-12 months	S-S	FS	Normal	<3.5	0	80-95	2-25 <sup>(4)</sup>	0
Sickle β <sup>0</sup> -Thalassemia <sup>(1)</sup>	Hemolysis and anemia by age 6-12 months	S-B <sup>0</sup>	FS	Decreased	3.5-7	0	80-92	2-15	0
Sickle-C Disease (Hb SC)	Milder hemolysis and anemia	S-C	FSC	Normal or decreased	NA <sup>(5)</sup>	0	45-50	1-5	45-50
Sickle β <sup>+</sup> -Thalassemia <sup>(1)</sup>	Milder hemolysis and anemia	S-B <sup>+</sup>	FSA or FS <sup>(3)</sup>	Normal or decreased	3.5-6	5-30	65-90	<2	0
Sickle Cell Trait		AS	FAS	Normal	<3.5	50-60	35-45	<2	0
Normal		AA	FA	Normal	<3.5	95-98	0	<2	0

\* By age 2 years.

\*\* These are typical findings, but due to the large variability observed in sickle hemoglobinopathies actual values may fall outside of these ranges

- 1 β<sup>0</sup> indicates a thalassemia mutation with absent production of β-globin; β<sup>+</sup> indicates a thalassemia mutation with reduced (but not absent) production of β-globin.
- 2 Hemoglobins reported in order of quantity (e.g. FSA = F>S>A); F, fetal hemoglobin; S, sickle hemoglobin; C, hemoglobin C; A, hemoglobin A. All abnormal results, including FAS, require confirmation with second newborn screen and Hb electrophoresis and confirmation testing at age 1 year.
- 3 The quantity of Hb A at birth is sometimes insufficient for detection.
- 4 Hb F levels in rare cases of Hb SS may be high enough to cause confusion with Hb S-Pancellular Hereditary Persistence of Fetal Hemoglobin (S-HPFH), a more benign disorder with less severe anemia and vaso-occlusion. In such cases, family studies and laboratory tests to evaluate the distribution of Hb F among red cells may be helpful.
- 5 The quantity of Hb A2 cannot be measured in presence of Hb C.

Modified with permission from Lane PA: Sickle cell disease. *Pediatr Clin North Am* 1996; 43:639-64.

---

### III. GUIDELINES FOR CARE OF CHILDREN WITH SICKLE CELL DISEASE

#### Definition of Levels of Care

This care plan assumes three levels of care for children with sickle cell disease:

1. The primary care physician;
2. A multidisciplinary program skilled in the nuances of sickle cell disease; and
3. Tertiary care for management of unusual or major complications.

Where skills and resources are appropriate, one medical site may provide several levels of care simultaneously. Whenever possible, the regular well-child care and immunizations should be managed by the primary physician, and disease-specific activities managed at the multidisciplinary program. The recommended timing and substance of visits will be described, but will vary with the needs of the patient, family and skills of the primary care provider. In general, infants should have monthly health care visits through the first six months, which can be alternated between primary and comprehensive sites, followed by visits every three to six months through 6 years of age.

These are guidelines, not standards. Their intent and the desired quality of care may be met by programs other than those described below.

The comprehensive program visits described below define counseling and teaching needs for age-specific sickle disease risks. This counseling may occur during the course of the normal primary provider visits listed if the primary caretaker is skilled in the problems of sickle diseases. Alternatively, the counseling and teaching goals may be met by outreach or in-home service providers such as public health nurses skilled in sickling diseases or tertiary program nurse clinicians. However, it is desirable for the child to visit the comprehensive program by 4 to 6 weeks of age and at least annually to establish the rapport and trust needed in case of major complications, and to keep abreast of new trends in the evaluation and treatment of sickle disease.

• Visits listed with the primary care provider correspond to the current American Academy of Pediatrics well-child guidelines.

• Refer to pages 18-24 for the three levels of the comprehensive care plan for children with sickle cell disease.

#### Clinic Requirements

• Most of the care for sickle cell patients occurs in an outpatient setting. Comprehensive outpatient management has been shown to reduce morbidity, lessen the frequency of complications, lessen psychological burdens, and reduce the rate of hospitalization.

#### Primary Care Requirements

• Primary caretakers should be familiar with and capable of providing the level of care outlined in The Management of Sickle Cell Disease.

• Primary providers should help facilitate patients' follow-up with the comprehensive sickle clinic.

#### Secondary Care Requirements

##### A. Diagnosis

- Ability to obtain and interpret results of screening and definitive tests for hemoglobinopathies.
- Ability to provide genetic counseling to affected families.
- Provide information about newborn screening program.

##### B. Ambulatory Care

- Provide general information about sickle cell diseases.
- Ability to follow guidelines for routine ambulatory care, as outlined in Management and Therapy of Sickle Cell Diseases.
- Access to educational materials to reinforce counseling.
- Participation of physicians, nurse practitioners and/or physician assistants with expertise in care of sickle cell patients.

- Participation of nursing staff with expertise in sickle cell issues. Nursing staff must have the skill and time available to provide educational support, perform phone triage, coordinate delivery of services with social services, and provide regular family outreach to ensure that families consistently receive care.
- Availability of vaccines specific to the infection risks of sickling diseases.
- Availability of social services to coordinate delivery of health care services and provide basic counseling.
- Access to nutrition services.
- Access to dental care with referral ability to those experienced in issues of infection and anesthesia specific to sickling diseases.
- Knowledge of community and family support resources for families of children with sickling diseases.

**C. Complications**

- Health care staff with experience and resources capable of identifying early signs of, and providing initial treatment for acute and chronic complications of sickle cell disease (such as: organ damage to include stroke, acute chest syndrome, splenic sequestration crises, sepsis, hand-foot syndrome, painful episodes, priapism, leg ulcers, avascular necrosis, sickle glomerulopathy, retinopathy, pulmonary hypertension, growth issues, and sickle lung disease).
- Proximity of tertiary level inpatient services, including surgical and medical services capable of providing initial care and stabilization for the above complications.
- Understanding the unique risks of surgery and anesthesia associated with sickling diseases.
- Availability to appropriately matched blood products.
- Availability of specialized pain management services, as well as availability of referral services for drug addictions.
- Access to academic and vocational counseling services.

**D. Adolescent and Adult Care**

- Transition strategy for patients transferring from pediatric care to adult care services.
- Birth control counseling and management.
- Genetic counseling
- Reproductive counseling and expertise in managing sickle cell patients through pregnancy and delivery.
- Understanding of the natural history of sickle cell disease and the development of approaches to monitor patients for chronic organ failure.

**E. Access and Availability**

- Patient access to expert physician/ medical staff available 24 hours a day. Staff must be knowledgeable in sickle hemoglobinopathies and capable of inpatient management.

**Comprehensive Sickle Cell Clinic: Tertiary Care**

**A. Diagnosis**

- Physician level genetic counseling services.
- Availability of pain management team for design of individualized pain treatment protocols and for application of coping techniques for chronic pain.
- Neuropsychologist with expertise in recognition of neurocognitive deficits common to sickle cell disease.
- Availability of neuro-imaging technology (e.g. MRI/MRA and angiography) for delineation of neurologic abnormalities encountered in sickle cell disease.
- Availability of trans-cranial doppler and specialists trained in assessing patients with sickle cell anemia to screen for the risk of stroke.
- Availability of diagnostic testing for delineation of complications of sickle cell disease (eg: pulmonary function testing, DEXA or bone density scan, abdominal US, echocardiography)
- Access to radiologists with experience differentiating sickle complications from other concerns.

- Access to MRI based quantitative assessment of iron overload (e.g. T2\*, Ferriscan or SQUID).

**B. Ambulatory Care**

All components of secondary care, plus:

- Social work and nutrition should have experience with sickle cell and have time dedicated to the clinic.

**C. Complications**

All components of secondary care, plus:

- Clinician available to provide or directly access definitive care for acute and chronic complications of sickling diseases.
- Participation in a tertiary care inpatient center capable of providing definitive medical and surgical care for complications of sickling diseases.
- Ability to design and maintain patients on chronic transfusion programs and iron chelation therapy, as well as understand and monitor for the complications of iron overload and chelation therapy.
- Familiarity with recent advances and ongoing experimental therapy in sickling diseases.
- Involvement in clinical trials designed to improve the quality of life and care provided to sickle cell disease patients.
- Access to a blood bank that performs extended red cell phenotyping and provides similarly matched blood products.

**D. Adolescent and Adult Care**

All components of secondary care, plus:

- Sickle cell experience.

**E. Access and Availability**

Same as secondary level.

**Age-Specific Activities**

**2- to 4-Week Check by PRIMARY CARE PROVIDER**

- Conduct usual 2-week, well-child care.
- Review results of state newborn metabolic screen, which includes hemoglobinopathy screening results.
- Check if Hepatitis B vaccine given at birth. If not, begin series.

**When Presumptive Positive Hemoglobinopathy Screen Becomes Available to PRIMARY PHYSICIAN**

- Discuss usual expectations of well-child care and practice arrangements, including after-hours coverage. It is important to encourage parents to maintain as normal a lifestyle as possible for children with sickle cell disease.
- No immediate confirmatory testing is necessary if the state lab has received two independent specimens as per standard policy for all newborns.
- Testing, including quantitation of hemoglobin types and for thalassemia, should be performed at 1 year of age after consultation or referral to a pediatric hematologist (a current listing is provided with the newborn screening program notification letter in Washington state).
- Begin Penicillin prophylaxis with Penicillin VK 125 mg BID orally to prevent pneumococcal sepsis.
- Provide prescription for folic acid supplements, 0.1 mg QD. Folate is consumed at increased rates in hemolytic anemias. It may be difficult finding liquid formulations; if preferred, please contact a pediatric hematologist.
- Emphasize the importance of observing for fever. The family should be taught to take a rectal temperature and appropriate use of antipyretics (e.g. avoiding antipyretics until the child has been evaluated for fever a health care provider). They should be taught to call the primary care provider immediately if fever develops.

- Emphasize the importance of fluid hydration.
- Make referral to your regional genetic counselor for assistance. A list of counselors with expertise in hemoglobinopathies is provided with the notification letter from the newborn screening program.
- Refer to WIC program for nutrition assistance (if eligible).
- Contact the County Health Department Children with Special Health Care Needs Program to have a public health nurse assigned.

### 6-Week Check by COMPREHENSIVE HEMOGLOBINOPATHY CARE PROGRAM (“COMPREHENSIVE PROGRAM”)

- Discuss the identified hemoglobinopathy with the family. Answer further questions. Briefly discuss genetic basis, and if not already done, refer for genetic counseling.
- Highlight the following problems:

**Fever:** Parents should check the child for fever if he or she is acting ill (demonstrate taking a rectal temperature). The family should be instructed to call the child’s physician or a tertiary care center if fever develops. Overwhelming sepsis should be discussed as well as its normal evaluation and management. The emergent risk of sepsis should be discussed and the need for immediate medical evaluation emphasized.

**Antibiotic Prophylaxis:** Should be started by 4 to 6 weeks of age in patients with SS and Sβ0 Thalassemia. Use Penicillin 125 mg BID until age 3 years, and 250 mg BID from age 3 to age 6 years (Gaston et al., 1986). Some comprehensive hemoglobinopathy programs recommend continued prophylactic treatment throughout life, however, a randomized prospective trial for older patients without surgical splenectomy or prior pneumococcal sepsis has demonstrated no benefit (Falletta et al., 1995). Sepsis risk in sickle genotypes other than HbSS (e.g. SC, Sβ+ Thalassemia) is lower and penicillin for these patients may not be indicated. Erythromycin (20 mg/kg divided into two daily doses) may be used in cases of penicillin allergy.

**Splenic Sequestration Crisis:** Instruct the family in recognition of splenic sequestration crisis and examination of the spleen. To learn about the exam and their child’s normal splenic size, they should practice this daily when the child is quiet. In cases of irritability, pallor, increasing abdominal girth and tenderness or respiratory distress, they should know to examine the spleen and, if enlarged, seek care at once.

**Other Medical Providers:** Discuss the importance of identifying the child’s sickle disease diagnosis with other medical providers.

- Initiate social work evaluation. Include discussion of family structure, strengths, coping mechanisms and financial resources. Discuss normal reactions to chronic illness in one’s child. Provide information about the parent support group. Where appropriate, refer for financial support for medical care. Where available, refer to a care coordination program.
- Confirm that second hepatitis B vaccine was given.
- If appropriate and not yet done, refer to WIC or alternate nutrition counseling.
- Coordinate nurse review care plan with family.
- If appropriate, confirm public health nurse referral.
- Begin teaching awareness about coping with common problems associated with children with chronic illnesses.

### 2-Month Check by the PRIMARY CARE PROVIDER

- Perform routine well-child care and physical exam, and demonstrate spleen exam. Reinforce home palpation of spleen.
- Reaffirm antibiotic prophylaxis and review emergency care arrangements.
- Reinforce teaching about the significance and management of fever. Discuss use of liberal fluids and of antipyretics in illness.
- Review folate therapy.
- Give standard 2-month immunizations.

**3-Month Check by COMPREHENSIVE PROGRAM/Teaching Goals for Age**

- Perform physical exam.
- Reinforce earlier teaching.
- Highlight:

**Pain Episodes, Sickle Dactylitis:** Discuss how “colic” or fussiness may be symptoms of pain. Discuss administration of liberal oral fluids and appropriate outpatient pain medications. If pain is not relieved by fluids, rest, and oral analgesics, the child should be medically evaluated. Make available resources for coping with pain.

**Causes of Sickling:** Discuss inciting causes or triggers of sickling. Include the kidney’s limited ability to conserve water and consequent need for liberal fluid intake. Discuss fluids appropriate for maintaining hydration in illness or hot weather. Discuss the effects of cold, infections and tiring.

- Social work update.
- Coordinating nurse review care plan with family.
- Review strategies to maximize health care access and introduce the patient and family to the Emergency Room, and reinforce strategies for positive interactions.

**4-Month Check by PRIMARY CARE PROVIDER**

- Perform routine well-child care.
- Give standard 4-month immunizations.
- Reinforce teaching about fever, splenic size, fluids, antibiotics, folic acid and pain therapy.
- Introduce coping strategies for blood draws and other invasive procedures.

**5-Month Check by COMPREHENSIVE PROGRAM/Teaching Goals for Age**

- Perform physical exam.
- Reinforce earlier teaching.
- Initiate dietary/nutrition counseling. Discuss the fact that good nutrition is important for the child’s health but will not correct sickle diseases. Growth should be followed at each visit. Enroll in WIC if appropriate.

- Increase folic acid dose to 0.25 mg QD.
- Highlight:

**Acute Chest Syndrome:** Discuss how respiratory distress or chest pain may signal problems and call for immediate medical evaluation. Normally, chest X-ray, CBC, retic and oximetry would be done. Antibiotics and oxygen should be administered, and transfusion may be provided in acute chest syndrome. Consider including antibiotic coverage for chlamydia and mycoplasma infection. Discuss the importance of expanding lungs to avoid atelectasis and recruit collapsed regions of lung. This is done with age-appropriate approaches.

**Neurologic Complications:** Discuss neurologic complications of sickle cell disease. The family should be taught to look for and seek help if seizures, severe headache, weakness, paralysis/paresis, vertigo, visual changes or loss of speech occur. Emergent medical evaluation for CVA should be performed; if fever is present, the possibility of meningitis should be considered. An exchange transfusion is indicated for stroke. The tertiary care program should be contacted for advice.

**Nurse:** Review care plan with family.

**6-Month Check by PRIMARY CARE PROVIDER**

- Perform routine well-child care.
- Reinforce previous teaching.
- Give standard 6-month immunizations.

**8- to 9-Month Check by COMPREHENSIVE/PRIMARY CARE PROGRAM/Teaching Goals for Age**

- Review and discuss prior teaching.
- Physical exam.
- Social service re-evaluation.
- Nurse review care plan with family.
- Influenza booster (initial two-dose vaccine during early first winter).

Note that the 8- to 9-month visit (and subsequent tri-monthly visits through 6 years of age) may either be performed as a single primary care visit, or separately as a primary care and comprehensive care visit, according to the expertise and comfort of the primary care provider.

**11- to 12-Month Check by COMPREHENSIVE/PRIMARY CARE PROGRAM/Teaching Goals for Age**

- History and PE.
- Labs: CBC, diff, retic, plt, BUN, Cr, Bili, Alk P, LDH, ALT, Iron Studies (other than FEP, ZPP), UA.
- Hemoglobin quantitation and thalassemia screen; electrophoresis or HPLC to quantitate hemoglobins (HbS, A, A2, F, C) and inclusion body or BCB prep. Should be done in an approved diagnostic laboratory.
- Tuberculin test, if indicated.
- Increase folic acid dose to 0.4 to 0.5 mg QD.
- Perform blood typing, and include sickle cell extended RBC matching panel (at a minimum RhD, Cc, Ee and Kell). Inform blood bank patient has sickle cell and should always receive blood with this extended matching.
- Introduce priapism.
- Confirm that genetic counseling occurred, and review.
- Nutrition counseling.
- Nurse review care plan with family.
- Routine immunizations/updates
- Annually in the fall, give booster influenza vaccine.

**14- to 15-Month Check by COMPREHENSIVE/PRIMARY CARE PROGRAM/Teaching Goals for Age**

- Routine well-child care.
- Review past teaching and examination.
- Social service case review.
- Routine immunizations/updates
- Nurse review care plan with family.

**17- to 18-Month Check by COMPREHENSIVE/PRIMARY CARE PROGRAM/Teaching Goals for Age**

- Routine well-child care.
- Routine immunizations/ updates
- Review past teaching and examination.
- Nurse review care plan with family.
- Distribute pain questionnaire.

**21-Month Check by COMPREHENSIVE/ PRIMARY CARE PROGRAM/Teaching Goals for Age**

- Review past teaching and examination.
- Social service case review.
- Discuss hyposthenuria and enuresis.
- Nurse review care plan with family
- Discuss Transcranial Doppler Study to identify children at increased risk for stroke (SS and S $\beta$ o patients)

**24-Month Check by PRIMARY CARE PROVIDER**

- Routine well-child care, review previous teaching.
- Pneumovax™ (PPV23), meningococcal, other routine immunizations/updates
- Increase folic acid to 0.8 to 1 mg QD.
- Discuss oral hygiene.

**2 1/2-Year Check by COMPREHENSIVE PROGRAM/Teaching Goals for age (Annually on the half-year)**

- Review need and importance of yearly studies.
- Review past teaching, PCN prophylaxis and exam.
- CBC, diff, plt, retic, BUN, Cr, Alk P, AST, Bili, LDH, Iron Studies
- Transcranial Doppler Study at 2 years of age and then yearly for patients with SS or S $\beta$ o-thalassemia, and some patients with S $\beta$ + thalassemia (should be done at a tertiary care facility by personnel trained to study patients with hemoglobinopathies).

- Introduce concepts of incentive spirometry for lung expansion when sick or during pain episodes. Discuss age appropriate substitutes for incentive spirometry.
- Evaluate for asthma.
- Review status of new potential treatments and interventions.
- Annually in the fall, give booster influenza vaccine.
- Social service PRN.
- Nurse review care plan with family.
- Review status of new potential treatments and interventions.
- Routine immunizations.
- If frequently transfused, please refer to guidelines for age 7 1/2 and older (below).

**3- and 4-Year Check by PRIMARY CARE PROVIDER**

- Routine well-child care.
- BP, UA with all subsequent annual visits.
- Ensure penicillin dose of 250 mg BID.
- Refer for routine dental care.
- Age four: Begin routine hearing and vision screening.
- Assess pain status, counsel family on pain management prevention and treatment.
- Begin coping strategy teaching with child.
- Assess and teach self-care skills.
- Developmental assessment.

**5-Year Check by PRIMARY CARE PROVIDER**

- Routine well-child care.
- Routine immunizations.

**5 1/2- and 6 1/2-Year Check by COMPREHENSIVE PROGRAM/Teaching Goals for Age**

- Review past teaching and examination.
- CBC, diff, plt, retic, BUN, Cr, Alk P, ALT, Bili, LDH, iron studies, UA.

- Social service PRN.
- Nurse review care plan with family.
- Promote self-care, reinforce coping strategies.
- Reinforce incentive spirometry during pain episodes and illness to prevent acute chest syndrome.
- Initiate school outreach and provide schools with resources about sickle cell disease.
- Continue Transcranial Doppler Study yearly for patients with SS or Sβ<sup>0</sup>-thalassemia and some patients with Sβ<sup>+</sup> thalassemia (should be done at a tertiary care facility by personnel trained to study patients with hemoglobinopathies).
- Review status of new potential treatments and interventions.
- Assess and teach self-care skills.
- Developmental and neuropsychologic assessment.
- If frequently transfused please refer to guidelines for age 7 1/2 and older (below).

**Annual Check by PRIMARY CARE PROVIDER**

- Routine well-child care.
- Pneumovax™ one-time booster five years after initial dose. Menactra booster every five years.
- Routine immunizations.
- Discontinue penicillin prophylaxis at age 6 years (children with a history of sepsis should continue on penicillin prophylaxis for life).
- Review yearly studies.

**Annually from age 7 1/2 to 13 years on the Half-Year Check by COMPREHENSIVE PROGRAM/Teaching Goals for Age**

- Review past teaching and examination.
- Discuss leg ulcers, priapism, delays in sexual maturation, sexual activity, smoking/drugs, activities and career goals as developmentally appropriate.
- Monitor/counsel on pain management.
- Monitor school progress and educational intervention as needed.

- Social service and nutritional evaluation as needed.
- Nurse review care plan with family.
- Review status of new potential treatments and interventions.
- Assess and teach self-care skills.
- Review yearly studies.
- Abdominal ultrasound for gall bladder stones, as needed for symptoms, and every other year routinely.
- Neuropsychologic evaluation q 2 to 3 years.
- Screen for depression and discuss coping strategies provide mental health services.
- Pulmonary function tests, CXR, O2 saturation, TCD, ophthalmology and dental evaluations yearly.
- EKG every other year.
- Echocardiogram, including documentation of tricuspid regurgitation jet velocity for all patients with a history of decreasing exercise tolerance / activity, multiple pneumonias, progressive restrictive lung disease. Timing of re-evaluation depends on results and clinical progression.
- Repeat meningococcal immunization q 5 years.
- Chronic transfusion programs, if needed, will usually be managed by tertiary care programs. Transfusion-dependent children are at risk of iron toxicity to the liver, heart, pancreas and pituitary gland. Ferritin, Fe, TIBC, as well as percent HbS are followed closely. At least annually, hepatic and renal function should be tested. Annual 24-hour Holter monitoring may be appropriate. Clinical and serologic pituitary function testing, including gonadotropins, can be used to monitor pituitary function. Quantitative assessment of organ iron accumulation is required, preferably non-invasively with specific MRI sequences (T2\* or Ferriscan), or SQUID. Liver biopsy to assess for portal fibrosis and chronic hepatitis may be needed if progressive liver damage is suspected. HIV and hepatitis serologies should be done yearly.

**Annually from 14 to 18 years:  
ADOLESCENCE ISSUES**

- Review past teaching and examination.
- Discuss leg ulcers, priapism, potential delays in sexual maturation, sexual activity, smoking/drugs, activities and career goals as developmentally appropriate.
- Genetic counseling directed toward patient early adolescence.
- Monitor/counsel on pain management.
- Monitor school progress and educational intervention as needed.
- Social service and nutritional evaluation as needed.
- Nurse review care plan with family.
- Assess and teach self-care skills. Distinguish self-care from transition.
- Begin to develop a plan for transition to adult care.
- Discuss birth control options.
- Review yearly studies.
- Neuropsychologic evaluation q 2 to 3 years.
- Screen for depression.
- Abdominal ultrasound for gall bladder stones, as needed for symptoms, and every other year routinely.
- Pulmonary function tests, CXR, O2 saturation, TCD, ophthalmology and dental evaluations yearly.
- EKG every other year.
- Echocardiogram including documentation of tricuspid regurgitation jet velocity for all patients with a history of decreasing exercise tolerance/ activity, multiple pneumonias, progressive restrictive lung disease. Timing of re-evaluation depends on results and clinical progression.
- Repeat meningococcal immunization q 5 years.

## Care Recommendations for SS and Other Sickle Syndromes

*Disease specific recommendations are noted by \*(see footnotes)*

### INFANCY Sickle and Primary Care Visits

AGE	PCP 2- to 4-week	SICKLE 6-week	PCP 2-month
<b>History/PE</b>	X	X	X
<b>Immunizations</b>	Hep B if needed		All routine immunizations, flu for household
<b>Medications</b>	PCN 125 mg PO BID, Folate 0.1 mg PO daily	Verify PCN 125 mg PO BID, Folate 0.1 mg PO daily	PCN 125 mg PO BID, Folic 0.1 PO daily
<b>Labs/ Diagnostics</b>	2nd NBS if needed		
<b>Education</b>	WCC, 24-hour access to care Review NBS results Fever, hydration	Basic pathophysiology of sickle cell and natural history, improved survival Identify family's preferred learning methods Inheritance/genetics Fever/sepsis/rectal temps Splenic sequestration Chronic illness awareness Discuss plan of care and emergency access Assess language preference	
<b>Referrals</b>	Sickle care, Public Health Nurse (PHN), WIC, genetic counselor	SW, verify PHN, WIC, GC	

# Care Recommendations for SS and Other Sickle Syndromes

## INFANCY Sickle and Primary Care Visits

AGE	SICKLE 3-month	PCP 4-month	SICKLE 5-month	PCP 6-month	SICKLE 7-month	PCP 9-month	PCP 12-month
<b>History/PE</b>	X	X	X	X	X	X	X
<b>Immunizations</b>		Routine		Routine, flu		Routine	Routine
<b>Medications</b>	PCN 125 mg PO, Folate 0.1 mg PO daily	PCN 125 mg PO BID, Folate 0.1 mg PO daily	Increase Folate to 0.25 mg PO daily	PCN 125 mg PO BID, Folate 0.25 mg PO daily	PCN 125 mg PO BID, Folate 0.25 mg PO daily	PCN 125 mg PO BID, Folate 0.25 mg PO daily	PCN 125 mg PO BID, Folate 0.25 mg PO daily
<b>Labs/Diagnostics</b>							
<b>Education</b>	Pathophysiology of sickling, dactylitis, pain episodes, avoidance of temperature extremes Review plan of care, visit schedule Review health care access, what to expect with ER and inpatient hospitalizations Spleen palpitation	Routine WCC, nutrition and fluids Fever, spleen, med review	Acute chest, nutrition/diet Cord blood pain/dactylitis/assessing pain in babies Fever/infection	Routine WCC, review acute chest and respiratory symptoms Fever, resp, spleen, pain	Review dactylitis, develop pain plan, review temperature triggers for pain Fever Review respiratory monitoring Introduce neurological complications	Routine WCC, nutrition, fluids Fever, resp, spleen, pain	Routine WCC, nutrition, fluids Fever, resp, spleen, pain
<b>Referrals</b>	Verify WIC, parent support, other PRN						

## Care Recommendations for SS and Other Sickle Syndromes

### TODDLER Sickle and Primary Care Visits

AGE	SICKLE 13-month	PCP 15-month	PCP 18-month	SICKLE 19-month	PCP 2-year	SICKLE 2-year
<b>History/PE</b>	X	X	X	X	X	X
<b>Immunizations</b>		Routine	Routine			PPV 23, Menactra
<b>Medications</b>	Increase Folate to 0.4-0.5 mg PO daily	PCN 125 mg PO BID, Folate 0.4-0.5 mg PO daily	PCN 125 mg PO BID, Folate 0.4-0.5 mg PO daily	PCN 125 mg PO BID, Folate 0.4-0.5 mg PO daily	PCN 125 mg PO BID, Folate 0.4-0.5 mg PO daily	Increase Folate to 0.8-1 mg/d PO daily
<b>Labs/Diagnostics</b>	Confirmatory labs*, annual labs, extended red cell phenotyping					Annual labs TCD*
<b>Education</b>	Review diagnosis, medications, genetic counseling and family planning Pain and development assessment Reinforce previous teachings	Routine WCC, nutrition and fluids Fever, resp, spleen, pain	Routine WCC, nutrition and fluids Fever, resp, spleen, pain	Create personal care plan for hospital use Introduce neurological risk and TCD* with next visit Introduce hyposthenuria and enuresis Review developmental behavior vs. pain Introduce pain diary	Routine WCC, nutrition and fluids Dental referral and oral hygiene Fever, resp, spleen, pain	Discuss neurological and TCD* results Review labs and pathophys Introduce additional pain triggers Introduce priapism Ensure dental care
<b>Referrals</b>						

## Care Recommendations for SS and Other Sickle Syndromes

### YEARLY Sickle Visits (Primary Care Visits continue per individual clinic protocol)

AGE	3 YEARS	4 YEARS	5 YEARS	6 YEARS
<b>History/PE</b>	X	X	X	X
<b>Immunizations</b>	As needed		Menactra booster 3 years after first dose if given between 2-6 1/2. If no Hib given previously, child should receive 1 <sup>st</sup> dose.	
<b>Medications</b>	Folate 0.8-1 mg/d PO Increase PCN to 250 mg BID	Folate 0.8-1 mg/d PO PCN 250 mg BID	Folate 0.8-1 mg/d PO PCN 250 mg BID	Folate 0.8-1 mg/d PO Discontinue PCN at age 6 years
<b>Labs/Diagnostics</b>	Annual labs TCD* Neuropsych (every 2-3 years)	Annual labs TCD*	Annual labs TCD*	Annual labs TCD*
<b>Education</b>	Distraction and stories with pain management Promote social opportunities, preschool Promote decision-making by offering choices	Start imagery work Promote activity/hobby as a long-term pain reliever (those involved cope with pain better) Promote decision-making by offering choices Have child help with simple chores (clean-up)	School readiness and accommodations, plan Early self-care (hydration) Encourage descriptions of pain Encourage monthly counseling for coping, stress Promote activity/hobby as a long-term pain reliever (those involved cope better with pain) Promote decision-making by offering choices Have child help with simple chores (clean-up)	Assess and build on child's disease understanding Self-care: hydration, initial pain management (non-meds), warmth YMCA, boys/girls club, art, drama, music Promote decision-making, natural consequences allow child to experience consequences
<b>Referrals</b>				

## Care Recommendations for SS and Other Sickle Syndromes

### YEARLY Sickle Visits

AGE	7 YEARS	8 YEARS	9 YEARS	10 YEARS
<b>History/PE</b>	X	X	X	X
<b>Immunizations</b>	PPV23 booster 5 years after first dose			
<b>Medications</b>	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily
<b>Labs/Diagnostics</b>	Annual labs Yearly studies	Annual labs Yearly studies Neuropsych	Annual labs Yearly studies	Annual labs Yearly studies
<b>Education</b>	Assess and build on child's disease understanding Self-care: hydration, initial pain management (non-meds), warmth Encourage social activities such as camps, school trips, outings, or sleep overs.	Assess and build on child's disease understanding Self-care: hydration, initial pain management (non-meds), warmth Sickle camp or other camp/social experience for children with special needs	Long-term interests Teasing, social opportunities Promote involvement in hobbies and extracurricular activities.	Explore teasing or bullying at school. Discuss advocating for self at school and other arena. Promote involvement in extracurricular activities and hobbies. Promote social gatherings with other families with sickle cell
<b>Referrals</b>				

## Care Recommendations for SS and Other Sickle Syndromes

### YEARLY Sickle Visits

AGE	11 YEARS	12 YEARS	13 YEARS	14 YEARS
<b>History/PE</b>	X	X	X	X
<b>Immunizations</b>				
<b>Medications</b>	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily
<b>Labs/Diagnostics</b>	Annual labs Yearly studies Neuropsych	Annual labs Yearly studies	Annual labs Yearly studies	Annual labs Yearly studies Neuropsych
<b>Education</b>	Assess and build on child's disease understanding Self-care: hydration, initial pain management, learn about meds Triggers Teach child to start keeping records of labs, studies, visits	Assess and build on child's disease understanding and self-care Asset-building with child: determine and build on strengths	Assess and build on child's disease understanding and self-care Ensure youth knows emergency plan and pain plan	Assess and build on child's disease understanding and self-care Begin to conduct at least part of visit without parent
<b>Referrals</b>				

## Care Recommendations for SS and Other Sickle Syndromes

### YEARLY Sickle Visits

AGE	15 YEARS	16 YEARS	17 YEARS
<b>History/PE</b>	X	X	X
<b>Immunizations</b>			
<b>Medications</b>	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily	Folate 0.8-1 mg PO daily
<b>Labs/ Diagnostics</b>	Annual labs Yearly studies	Annual labs Yearly studies	Annual labs Yearly studies Neuropsych
<b>Education</b>	Assess and build on child's disease understanding and self-care Discuss family planning, birth control, genetics Discuss drugs and alcohol especially in relation to sickle cell as well as interactions with opiates.	Assess and build on child's disease understanding and self-care Encourage youth to start making own appointments, tracking progress, and managing medications with parental help Discuss drugs and alcohol especially in relation to sickle cell as well as interactions with opiates.	Assess and build on child's disease understanding and self-care Introduce to adult hematology, tour adult facility, arrange adult primary care provider Discuss drugs and alcohol especially in relation to sickle cell as well as interactions with opiates.
<b>Referrals</b>			

---

## IV. GUIDELINES FOR PAIN MANAGEMENT

### Pain Related to Sickle Cell Disease

Pain is the hallmark of sickle cell disease. The pain associated with sickle cell is complex in that it can be acute, recurring, chronic or a mixture of these. Unlike other causes of pain, there may be no biomarkers or physical indicators for the clinician to use to evaluate pain, and over time patients may adapt to the pain and objective findings such as elevations in heart rate or blood pressure are not always observed.

Trust in the patient's report and eliciting a good description of pain are therefore critical components in the evaluation of sickle pain, and in the differentiation between sickle pain and other etiologies of pain. Management of pain must be individualized to each patient and plans of care should be created that work best for each person. Treatment should, however, always be multimodal incorporating the alleviation of triggers in addition to non-pharmacological and pharmacological approaches.

**Severity:** Varies from mild to extremely intense.

**Character:** Deep, aching, tiring, fatiguing, relentless. Described as "body chewing," "body biting" or "bone breaking."

**Developmental Aspects:** Can occur as early as 4 to 9 months of age when fetal hemoglobin levels are diminished.

**Region:** Can occur in any part of the body and may involve single or multiple body parts. Common complaints:

- Extremity pain
- Abdominal pain
- Back pain

Pain due to swelling in hands and feet from dactylitis typically occurs in children under 3 years of age.

**Frequency:** Sickle cell pain forms a continuum from acute to chronic:

- 30% never or rarely have pain
- 50% have few episodes
- 20% have frequent, severe episodes (6% of patients account for 30% of all painful episodes)

### Precipitating Factors:

- Infection
- Hypoxemia
- Dehydration
- Fatigue
- Exposure to cold, changes in weather
- Strenuous exercise
- Sleep apnea

### General Principles of Pain Management

A number of general principles can be applied to the management of pain in sickle cell disease.

- A. Pain must be viewed within a chronic disease continuum: Promotion of wellness and development while also consistently addressing pain is necessary.
- B. Health care professionals have the accountability/responsibility for using a proactive, not a reactive approach. Multiple interventions and approaches should be integrated in the management of pain, not simply medication alone.
- C. Emphasize the value of a system-wide approach
  1. Effective pain management is contingent on involvement by administration, managers, practitioners and family members.
  2. Role of child and family:
    - a. To expect that pain be treated/integrated into a plan of treatment
    - b. To participate in designing and modifying plan, informing providers of personal belief system that impacts care choices.
    - c. To obtain education and support
  3. Role of administration, managers, and practitioners:
    - a. Pain relief is a quality assurance/continuous quality improvement issue for children with chronic illness. Care effectiveness must be evaluated.

- b. Develop standards of care/clinical guidelines for common pain problems such as:  
Emergency room treatment of sickle cell pain episode, home management procedures, and developing multiple healthy coping strategies.
- D. Adequate assessment is the cornerstone of therapy
1. Pain assessment should be developmentally appropriate and a routine part of the inpatient and outpatient care of children with these chronic diseases.
  2. The child's complaints of pain should be believed. Verbal self-report is primary and cannot be disputed.
  3. See Sickle Cell Pain Assessment diagram on page 31.
- E. Assess and develop a plan of care with the first episode of pain
1. Online "Pain profiles" that are accessible or transferable, regardless of site of care.
  2. Summarizes pain history and details the pain care plan based on child and family input and past experiences. Plan should include both non-pharmacologic and pharmacologic details. Plan is modified and updated on a real-time basis.
  3. Life records: Eliminates the need for repeated questioning of child/parents(s), particularly as they enter different hospital areas (ER, clinic, inpatient, OR).
  4. A pain problem list should be instituted so that pain stemming from the disease and its treatment can be isolated and treated appropriately.
  5. Hand-held records: Empowers child and family.
- F. Guidelines for clinical care
1. Avoid the use of the term pain "crisis" as this can contribute to a sense of anxiety. A more appropriate term is "pain episode."
  2. Please refer to the management of sickle cell pain algorithms and charts in this document.
  3. General principles of pharmacologic management:
    - a. Severe pain is an emergency and must be treated accordingly.
    - b. Use a stepwise approach to pharmacologic therapy that includes: initial therapy with NSAIDs, add low potency short acting opioids if necessary, change to higher potency short acting opioids if needed, add long acting opioids and adjuvant therapies as needed.
    - c. Assessment and re-assessment must be ongoing throughout the course of pain treatment.
    - d. Be certain that adequate analgesics are given to allow nighttime sleep.
    - e. In the majority of cases, oral routes of analgesia are effective and should be used.
    - f. Scheduled administration to prevent anticipated return of pain is appropriate, unless pain is truly episodic and unpredictable.
    - g. Avoid noxious routes of administration (e.g. I.M. injections) since children will often deny pain due to a fear of needles.
    - h. Addiction is rare. Fear of addiction should not restrict adequate opioid administration.
    - i. Do not use placebos.
    - j. Involve the child and his/her family in the treatment, and respect personal preferences and cultural diversity.
    - k. If dose reduction is indicated, it should be done slowly to avoid precipitating severe pain withdrawal.
    - l. Side effects should be anticipated and treated.
    - m. The goal of therapy should be adequate analgesia to allow increased function as determined by the patient, family and staff.
    - n. Although there are guidelines for starting doses, there is no maximum dose for opioids. The right dose is the dose that is adequate to relieve the pain without undue toxicity.
    - o. Assess often for respiratory compromise, as hypoxemia may contribute to episodes of acute chest syndrome. Incentive spirometry while on opiates.

4. Complimentary non-pharmacologic strategies-developmental approaches:

**Infants**

- Explanations:* Caregiver teaching
- Distractions:* Music/mobiles, soothing talk, soft or a novel voice, calm demeanor, oral-motor stimulation (pacifiers, non-nutritive sucking)
- Containment:* Holding/cuddling/swaddling, positioning, pacifier
- Physical:* Massage (applicability/efficacy being determined)

**Toddlers/Preschoolers**

- Distraction:* Pop-up books, magic circle/magic game, puppets, kaleidoscopes, counting ABCs, music-sing-along songs, squeezing on koosh ball
- Distraction with breathing:* Pinwheel, blowing bubbles, “meow-woof” breathing, party blowers
- Breathing/relaxation:* “Go limp as a ragdoll,” or “You’re blowing hurt away,” or ask the child to yawn, choo-choo like a train
- Imagery:* Stories-use images familiar to the child
- Explanations:* Before procedure, provide concrete and brief explanations to caregiver and child; during procedure, provide sensory information and emphasize informational affective aspects of the experience; after procedure, use therapeutic play
- Physical:* Massage, heat, acupuncture, acupressure, Transcutaneous Electrical Nerve Stimulation (TENS)

**School-Age/Adolescents**

- Modeling/desensitization:* Explanations to child and family
- Distraction (younger):* Pop-up books; counting ABCs, puppets, kaleidoscopes, music with I-Pod, DVD player, video games
- Imagery (older):* Pain switch, familiar images with stories, biofeedback

## Common Pain States Associated with Sickle Cell Disease

Pain States	Clinical Signs & Symptoms	Signs & Underlying Cause	Special Features & Considerations
<b>Acute Painful Event</b>	<ul style="list-style-type: none"> <li>Sudden onset</li> <li>Pain in any or all parts of the body</li> </ul>	<ul style="list-style-type: none"> <li>Vaso-occlusion</li> <li>Endothelial damage</li> <li>Inflammation</li> </ul>	<ul style="list-style-type: none"> <li>Unpredictable, recurrent</li> <li>Great variability</li> <li>All ages</li> </ul>
<b>Acute Hand-Foot Syndrome (Dactylitis)</b>	<ul style="list-style-type: none"> <li>Painful dorsal swelling of hands and feet</li> </ul>	<ul style="list-style-type: none"> <li>Symmetrical infarcts of metacarpal and metatarsal bones due to obstruction of developing blood vessels</li> </ul>	<ul style="list-style-type: none"> <li>More common in childhood</li> <li>Often first manifestation of disease (occurs as early as 6 months of age)</li> </ul>
<b>Acute Inflammation of Joints</b>	<ul style="list-style-type: none"> <li>Painful, swollen joints</li> </ul>	<ul style="list-style-type: none"> <li>Vaso-occlusion/injury</li> <li>Inflammation</li> <li>Infected joints</li> <li>Gout</li> </ul>	<ul style="list-style-type: none"> <li>May accompany dactylitis</li> <li>Acute flare-ups as isolated events</li> <li>Septic arthritis is rare but may occur</li> </ul>
<b>Acute Chest Syndrome</b>	<ul style="list-style-type: none"> <li>Chest pain, particularly rib and substernal area</li> <li>Chest pain posteriorly (upper back)</li> <li>Fever, tachypnea, and/or hypoxia</li> </ul>	<ul style="list-style-type: none"> <li>Pulmonary infiltrate</li> <li>May be associated with infarction, infection or hemorrhage, or any combination of these</li> <li>Unilateral pain (splinting from atelectasis)</li> </ul>	<ul style="list-style-type: none"> <li>May require transfusion and can be fatal</li> <li>Common cause of mortality in children and adults</li> </ul>
<b>Splenic Sequestration</b>	<ul style="list-style-type: none"> <li>Left upper-quadrant pain</li> <li>Marked pallor</li> <li>Sudden decrease in hemoglobin concentration</li> <li>Enlarged spleen</li> </ul>	<ul style="list-style-type: none"> <li>Blood trapped in the spleen</li> </ul>	<ul style="list-style-type: none"> <li>Can be catastrophic in children, with possibility of circulatory collapse</li> <li>Insidious onset in adults</li> <li>Occurs in older children and adults with HbSC and sickle <math>\beta^+</math>-thalassemia</li> </ul>
<b>Intrahepatic Sickling or Hepatic Sequestration</b>	<ul style="list-style-type: none"> <li>Right upper-quadrant pain</li> <li>Sudden decrease in hemoglobin</li> <li>Enlarged liver</li> </ul>	<ul style="list-style-type: none"> <li>Blood pooling in the liver</li> </ul>	<ul style="list-style-type: none"> <li>Occurs more commonly in adults</li> </ul>
<b>Abdominal and Intra-abdominal Pain</b>	<ul style="list-style-type: none"> <li>Jaundice</li> <li>Diffuse abdominal pain</li> <li>Enlarged spleen</li> </ul>	<ul style="list-style-type: none"> <li>Cholelithiasis</li> <li>Gastritis</li> <li>Constipation secondary to opioid therapy</li> <li>Splenic infarction</li> </ul>	<ul style="list-style-type: none"> <li>Can be initial manifestation of acute chest syndrome</li> <li>Involve surgery if severe symptoms</li> </ul>
<b>Priapism</b>	<ul style="list-style-type: none"> <li>Painful erection</li> </ul>	<ul style="list-style-type: none"> <li>Sickling in sinusoids of penis</li> </ul>	<ul style="list-style-type: none"> <li>May be chronic or stuttering (intermittent)</li> </ul>
<b>Avascular Necrosis of Femur or Humerus</b>	<ul style="list-style-type: none"> <li>Prolonged, constant bone pain</li> <li>Shoulder pain</li> <li>Knee pain</li> <li>Hip pain</li> </ul>	<ul style="list-style-type: none"> <li>Associated with bone infarction, sickle arthritis</li> </ul>	<ul style="list-style-type: none"> <li>Physical therapy may be useful for reducing pain and maintaining function</li> </ul>
<b>Chronic Neuropathic Pain</b>	<ul style="list-style-type: none"> <li>Pain in back, lower extremities, other sites</li> <li>Spontaneous</li> <li>Lancinating</li> <li>Burning</li> </ul>	<ul style="list-style-type: none"> <li>Older adults: disc disease, infections</li> <li>Collapsed vertebrae</li> <li>Iron overload neuropathy</li> </ul>	<ul style="list-style-type: none"> <li>Must be considered in patients with a decreased response to opioids</li> <li>Physical therapy</li> <li>Consider medications for neuropathic pain such as gabapentin</li> <li>Treatment modalities may require days or weeks before taking effect</li> <li>Creates chronic pain state</li> </ul>

Adapted from APS guidelines

## Pain Assessment Tools

There are a variety of tools available to measure pain severity and functional impact. The following are a variety of tools to choose from. The practitioner should use what is most appropriate for the patient and situation.

### Assessment Tool 1: The Oucher

#### *Which part of the scale should be used?*

If children can count to 100, they can use the numerical scale; if not, they should use the photographic scale.

#### *How does one use the Oucher?*

A. Let children practice using the Oucher.

1. Ask them to recall times they hurt in the past.
2. Have them describe these episodes to you and then rate them on the Oucher.

B. Collect data and convert to scores.

1. After re-explaining the scale, ask, "How much hurt do you have right now?"
2. If the child uses the numerical scale, the number they give is the Oucher score; if the child uses the photographic scale, the picture they select is converted to the appropriate predetermined score shown on the oucher (0, 20, 40, 60, 80 or 100).

### Assessment Tool 2: Pain Intensity Number Scale

#### *Children Developmentally Later School-Age and Adolescent*


Instructions:

1. "I need to know how much pain you have because I can't feel your pain. I want you to use a scale so you can tell me how much pain you have right now."
2. "The numbers between 0 and 10 represent all the pain a person could have. Zero means no pain and 10 means pain as bad as it could be. You can use any number between 0 and 10 to let me know how much you have right now."
3. "Give your pain a number between 0 and 10 so I will know the intensity of the pain you feel now."
4. Record the pain intensity on the nursing flow sheet as 0/10, 1/10, 2/10, etc.  
(Wilke, D.J., et. al. The Hospice Journal, 6(1), 1-13. Essentials of Pain Management: A Nursing Handbook. Optioncare: Seattle, WA.)
5. For younger children, substitute the FACES pain scale for number scale.

### Pain Intensity FACES Scale

#### **FACES PAIN SCALE - REVISED (FPS-R) for children over age 3**

Point to the face that shows how much you hurt.



These faces show how much something can hurt. The left-most face shows no pain. The faces show more and more pain up to the right-most face - it shows very much pain.

### **Assessment Tool 3: Work Graphic Rating Scale**

#### *Children Developmentally Later School-Age and Adolescent*

Instructions:

1. Place a straight up-and-down mark on this line to show how much pain you have.

---

No pain

Little pain

Medium pain

Large pain

Worst possible pain

2. Record the pain intensity on the nursing flow sheet as “none,” “little,” “medium,” “large” or “worst possible.”


### **Assessment Tool 4: Functional Assessment**

Record functional assessment of pain on flow sheet, for example:


- “Unable to sit up or walk”
- “Able to eat”
- “Able to do self care”

Adapted from APS guidelines

# Sickle Cell Pain Assessment




## Treatment Flowchart




Adapted from APS guidelines

# Management of an Episode of Acute Pain in Sickle Cell Disease



Continued on next page

**Management of an Episode of Acute Pain in Sickle Cell Disease** *Continued from previous page*



These are the American Pain Society guidelines. Individual institutions, including Seattle Children's Hospital, may have differing practices.

Adapted from APS guidelines

## Vaso-Occlusive Pain

Diagnosis	Monitoring	Diagnostic (if not previously obtained)	Fluids, Nutrition, General Care	Medications/Treatments	Discharge Criteria
Vaso-occlusive pain in a child with sickle cell disease	<ol style="list-style-type: none"> <li>1. Vital signs q 4 hr</li> <li>2. Record I + O, daily weight</li> <li>3. Continuous pulse ox. if any respiratory symptoms present, or if on parenteral opiates</li> <li>4. Consider CR monitor</li> </ol>	<ol style="list-style-type: none"> <li>1. CBC, diff., plt count and retic count initially (compare with patient's baseline data); consider a hold tube for the blood center (for later type and cross) if severe anemia suspected or transfusion anticipated</li> <li>2. CXR: low threshold if cough or any respiratory signs or symptoms are present, or develop after admission; encourage incentive spirometry prior to CXR</li> <li>3. Blood culture if &gt;38.2°C; urinalysis, urine culture and other cultures (e.g. CSF) as indicated</li> <li>4. Consider diagnostic tests to evaluate possible non-sickle causes of pain (e.g. abdominal ultrasound, liver function tests for RUQ to R/O cholelithiasis and cholecystitis)</li> </ol>	<ol style="list-style-type: none"> <li>1. IV + PO 1.25 x maintenance. Increased fluids only if patient is dehydrated and/or insensible losses are increased (e.g. persistent fever); avoid excessive fluids, which may worsen respiratory status</li> <li>2. Avoid IV fluid bolus unless clinically dehydrated or clinically indicated (not for pain alone)</li> <li>3. Incentive spirometry—10 breaths q 2 hr. from 0800-2200 and while awake.</li> <li>4. Encourage ambulation and activity</li> </ol>	<ol style="list-style-type: none"> <li>1. Follow patient-specific care plan if available; if not, follow generic steps below</li> <li>2. Offer heat pads, imagery, relaxation methods or other comfort measures as adjunct to pharmaceuticals.</li> <li>3. A parenteral or oral non-steroidal anti-inflammatory agent if no contraindication (i.e. gastritis, ulcer or renal impairment)</li> <li>4. If no established pain plan: Morphine sulfate 0.1 mg/kg/ dose IV q 2 hr. or 0.01-0.1 mg/kg/hr. continuous infusion or via PCA (doses above 0.1 mg/kg/hr. may be required but should be used with caution); alternative analgesics may be used in individual cases*</li> <li>5. Reassess pain control at least twice daily and after every intervention; analgesics may be weaned as tolerated by decreasing dose, not by prolonging interval between doses; discuss analgesic changes with patient/family</li> <li>6. Start oral opiates as soon as tolerated from a gastrointestinal standpoint, even if requiring IV opiates</li> <li>7. Consider pain team consultation</li> <li>8. Ceftriaxone 75mg/kg q 24 hr if febrile (prophylactic penicillin may be discontinued while on broad-spectrum antibiotics)</li> <li>9. Continue prophylactic folic acid, if applicable</li> <li>10. O<sub>2</sub> by nasal cannula as needed to keep O<sub>2</sub> saturation &gt; 93%</li> <li>11. Colace or laxative to prevent narcotic-induced constipation</li> <li>12. See other Clinical Care Paths for acute chest syndrome, acute anemia crisis, stroke, priapism, if present</li> <li>13. Avoid use of ice or cold packs</li> </ol>	<ol style="list-style-type: none"> <li>1. Taking oral fluids well and able to take all PO meds (e.g. prophylactic penicillin) if applicable</li> <li>2. Adequate pain relief on oral analgesics</li> <li>3. Afebrile &gt;24 hr and negative cultures &gt;24 hours if applicable</li> <li>4. Resolution of any pulmonary symptoms or documentation of adequate oxygenation on room air</li> </ol>

\* These are the American Pain Society guidelines. Individual institutions, including Seattle Children's Hospital, may have differing practices.

Modified from Mountain States Regional Genetic Services Network, 1996

## Sedation Scale and Indications for Action\*

Sedation Scale		Action Required
S	Sleeping, easily aroused	None Consider monitoring O <sub>2</sub> saturation
1	Awake and alert	None Consider monitoring O <sub>2</sub> saturation
2	Occasionally drowsy, easy to arouse	None Consider monitoring O <sub>2</sub> saturation
3	Frequently drowsy, arousable, drifts off to sleep during conversations	Physically stimulate Decrease or discontinue the opioid Monitor O <sub>2</sub> saturation
4	Somnolent, minimal or no response to stimuli	Discontinue opioid and consider titration of naloxone Monitor O <sub>2</sub> saturation

\* Adapted from: McCaffery, M., & Pasero, C.L. (1999) Pain: Clinical Manual (2nd ed.). St. Louis: Mosby, Inc.

Note: The above scale and recommendations are not appropriate for patients who are terminally ill, have developed a tolerance to respiratory depression, or in whom sedation is not caused by opioids.

## NSAIDs Dosing Data

Medication	Usual Dose for Adults and Children ≤50 kg Body Weight	Usual Dose for Children <sup>1</sup> and Adults <sup>2</sup> ≤50 kg Body Weight
<b>Acetaminophen and Over-the-Counter NSAIDs</b>		
Acetaminophen <sup>3</sup>	650 mg q 4 hr 975-1,000 mg q 6 hr	10-15 mg/kg q 4 hr (oral) 15-20 mg/kg q 4 hr (rectal)
Ibuprofen	400-800 mg q 6 hr	10 mg/kg q 6-8 hr <sup>4</sup>
Ketoprofen (Orudis)	25-75 mg q 6-8 hr	0.5 mg/kg q 6 hr
Naproxen (Naprosyn)	500 mg initially, then 250 mg q 6-8 hr	5-7 mg/kg q 8-12 hr
Naproxen sodium (Anaprox)	550 mg initially, then 275 mg q 6-8 hr	
<b>Parenteral NSAIDs</b>		
Ketorolac tromethamine <sup>5,6</sup> (Toradol)	30 mg initially, then 15-30 mg q 6 hr, parenteral dose not to exceed 5 days or 120 mg/day	0.5 mg/kg q 8 hr intravenously <sup>5,6</sup>

<sup>1</sup> Only medications that are FDA-approved as analgesics for children are included.

<sup>2</sup> Acetaminophen and NSAID dosages for adults weighing less than 50 kg should be adjusted for weight.

<sup>3</sup> Acetaminophen lacks the peripheral anti-inflammatory and antiplatelet activities of other NSAIDs.

<sup>4</sup> Ibuprofen is not FDA-approved for use in children as an over-the-counter medication. It has FDA approval for use in children as a prescription medication for fever; however, some clinicians have had experience in prescribing ibuprofen for pain relief in children.

<sup>5</sup> For short-term use only.

<sup>6</sup> Has the same GI toxicities as oral NSAIDs. Safety and efficacy not established for use in children.

Modified from "Guidelines for the Management of Acute and Chronic Pain in Sickle Cell Disease," American Pain Society, August 1999. These are the American Pain Society guidelines. Individual institutions, including Seattle Children's Hospital, may have differing practices.

## Opioid Dosing Table

(For patients without established pain plan)

Opioid Agonist	Approx Equianalgesic Oral Dose	Approx Equianalgesic Parenteral Dose	Recommended Starting Dose (Adults > 50 kg) Oral	Recommended Starting Dose (Adults > 50 kg) Parenteral	Recommended Starting Dose (Children, adults < 50 kg) <sup>1</sup> Oral	Recommended Starting Dose (Children, adults < 50 kg) <sup>1</sup> Parenteral
Morphine <sup>2</sup>	30 mg q 3-4 hr (around-the-clock dosing); 60 mg q 3-4 hr (single dose or intermittent dosing)	10 mg q 3-4 hr	10-30 mg q 3-4 hr	5-10 mg q 2-4 hr	0.3 mg/kg q 3-4 hr	0.1 mg/kg q 3-4 hr
Codeine <sup>3</sup>	200 mg q 3-4 hr		15-60 mg q 3-4 hr	Not recommended	0.5-1 mg/kg q 3-4 hr	Not recommended
Hydromorphone <sup>2</sup> (Dilaudid)	7.5 mg q 3-4 hr	1.5 mg q 3-4 hr	6 mg q 3-4 hr	1.5 mg q 3-4 hr	0.06 mg/kg q 3-4 hr	0.015 mg/kg q 3-4 hr
Oxycodone	30 mg q 3-4 hr	Not available	10 mg q 3-4 hr	Not available	0.15-0.2 mg/kg q 3-4 hr	Not available
<b>Opioid Agonist – Antagonist and Partial Antagonist</b>						
Nalbuphine (Nubain)	Not available	10 mg q 3-6 hr	Not available	10 mg q 3-6 hr	Not available	0.1 mg/kg q 3-6 hr

Note: Tables vary in the suggested doses that are equianalgesic to morphine. Clinical response is the criterion that must be applied for each patient: Titration to clinical response is necessary. Because there is not complete cross-tolerance among these drugs, it is usually necessary to use a lower than equianalgesic dose when changing drugs and to retitrate to response.

Caution: Recommended doses do not apply to patients with renal or hepatic insufficiency or other conditions affecting drug metabolism and kinetics.

<sup>1</sup> Caution: Doses listed for patients with body weight less than 50 kg cannot be used as initial starting doses in babies less than 6 months of age. Consult *Clinical Practice Guideline for Acute Pain Management: Operative or Medical Procedures and Trauma section on management of pain in neonates for recommendations.*

<sup>2</sup> For morphine (hydromorphone and oxymorphone), rectal administration is an alternate route for patients unable to take oral medications, but equianalgesic doses may differ from oral and parenteral doses because of pharmacokinetic differences.


<sup>3</sup> Caution: Codeine doses above 65 mg often are not appropriate due to diminishing incremental analgesia with increasing doses, but continually increasing constipation and other side effects.

Caution: Doses of aspirin, ibuprofen and acetaminophen in combination opioid/NSAID preparations should be avoided to prevent inadvertent toxicity from the non-opiate component.


These are the American Pain Society guidelines. Individual institutions, including Seattle Children's Hospital, may have differing practices.

# V. ALGORITHMS AND COMPLICATION-SPECIFIC GUIDELINES

## Anemia Algorithm



# Fever and Sepsis Algorithm



## Acute Chest Syndrome

Diagnosis	Monitoring	Diagnostic (if not previously obtained)	Fluids, Nutrition, General Care	Medications/ Treatments	Discharge Criteria
<p>Definition: A new infiltrate on CXR in a patient with sickle cell disease.</p>	<ol style="list-style-type: none"> <li>1. Vital signs q 2-4 hr.</li> <li>2. Continuous pulse oximetry.</li> <li>3. Consider CR monitor.</li> <li>4. Record I + O, daily weight</li> </ol>	<ol style="list-style-type: none"> <li>1. CBC, diff., platelet count and reticulocyte count initially and daily until improving (compare with patient's baseline values).</li> <li>2. CXR. Repeat for clinical deterioration looking for progression. May need serial CXRs.</li> <li>3. Type and cross match (minor-antigen-matched if available, sickle negative, leukocyte depleted RBC) to have blood available. Obtain red cell extended phenotyping for sickle cell patients if not done previously (at a minimum type for RhD, Cc, Ee and Kell).</li> <li>7. Blood cultures if T &gt; 38.2°C or history of recent fever.</li> <li>8. Capillary or arterial blood gas and assessment by PICU team for severe illness.</li> </ol>	<ol style="list-style-type: none"> <li>1. Maintain "euvoemia." IV + PO 1-1.25 x maintenance. More fluid is appropriate only if patient is dehydrated or if insensible losses are increased (e.g. persistent fever).</li> <li>2. Incentive spirometry x 10 breaths q 2 hr. during the day (0800-2200), if awake at night, and prior to all CXRs.</li> <li>3. Encourage ambulation, activity.</li> </ol>	<ol style="list-style-type: none"> <li>1. Oxygen to maintain O<sub>2</sub> saturation &gt; 93%</li> <li>2. Ceftriaxone 75mg/kg Q 24 hr. IV. (Prophylactic penicillin may be discontinued while on broad-spectrum antibiotics.)</li> <li>3. Azithromycin 10mg/kg PO x1, then 5 mg/kg PO QD days 2-5, or other macrolide antibiotic.</li> <li>4. Chest physical therapy if consolidation is present.</li> <li>5. Follow patients specific pain plan. If not available consider morphine 0.1 mg/kg IV q 2 hr. or 0.01 - 0.1 mg/kg/hr. continuous infusion or PCA for severe pain. Alternative analgesics (but not demerol) may be used in individual cases. Adequate pain relief is essential to avoid splinting improve respiratory dynamics that worsens respiratory status.</li> <li>6. Consider round the clock bronchodilators, especially if patient has history of wheezing or asthma. Some patients benefit even if not clinically obstructed.</li> <li>7. Consider use of BiPAP or CPAP if not improving with routine measures.</li> <li>8. Consider red cell transfusion for progressive respiratory decline despite incentive spirometry and #1-6 above. Pain control and incentive spirometry are commonly under-utilized. Transfuse initially if severely ill.               <ol style="list-style-type: none"> <li>a. Simple transfusion to a HCT of 30% (no clear benefit to exchange transfusion).</li> <li>b. Exchange transfusion for patients with progressive disease and a Hct &gt; 27% or lack of improvement &gt; 36 hrs post simple transfusion. Target a Hct of 30% and Hb S or Hb S + C &lt; 30 %. (May require transfer to ICU for erythrocytapheresis). Remove femoral or central venous catheters as soon as possible after exchange transfusion to reduce risk of thrombosis.</li> </ol> </li> <li>9. See other Clinical Care Paths for acute anemic crisis, stroke, priapism, if present.</li> <li>10. Continue prophylactic folic acid, if applicable.</li> </ol>	<ol style="list-style-type: none"> <li>1. Off O<sub>2</sub>.</li> <li>2. Afebrile &gt; 24 hr and negative cultures for 24 hours (if applicable).</li> <li>3. Good oral intake, able to take all oral medications including antibiotics.</li> <li>4. Adequate pain relief (if needed) with oral analgesics.</li> <li>5. Discharge instruction completed regarding home use of incentive spirometry while on opiates.</li> <li>6. Follow-up plans coordinated with hematology service. CXR to establish new baseline in 2-3 months.</li> </ol>

Modified from Mountain States Regional Genetic Services Network, 1996

## Stroke or Acute Neurological Event

Diagnosis	Monitoring	Diagnostic (if not previously obtained)	Fluids, Nutrition, General Care	Medications/ Treatments	Discharge Criteria
Stroke or acute neurologic event in child with sickle cell disease	<ol style="list-style-type: none"> <li>1. ICU admission first 24 hr and until stable</li> <li>2. Vital signs, neuro checks q 2 hr</li> <li>3. CR monitor</li> <li>4. Continuous pulse ox</li> <li>5. Record I + O, daily weight</li> </ol>	<ol style="list-style-type: none"> <li>1. CBC, diff, platelet count, reticulocyte count initially (compare with patient's baseline data)</li> <li>2. Coagulation profile; consider evaluation for hypercoagulability</li> <li>3. Blood and urine cultures if febrile</li> <li>4. Type and cross-match (minor-antigen-matched if available (at a minimum RhD, Cc, Ee and Kell), sickle-negative, leukocyte-depleted RBC) for exchange transfusion (consider erythrocytapheresis)</li> <li>5. Electrolytes initially and daily until stable</li> <li>6. Emergent CT scan or MRI/MRA to exclude intracranial hemorrhage. MRI/MRA when stable if not obtained initially</li> <li>7. Consider CSF culture if febrile and no contraindication present</li> <li>8. Consider hypercoagulation/thrombosis evaluation</li> </ol>	<ol style="list-style-type: none"> <li>1. IV + po 1-1.25 x maintenance</li> </ol>	<ol style="list-style-type: none"> <li>1. Oxygen to maintain O<sub>2</sub> saturation &gt; 93%</li> <li>2. Rx seizures if present</li> <li>3. Rx increased intracranial pressure if present</li> <li>4. Broad-spectrum IV antibiotics if febrile</li> <li>5. If applicable and not on broad-spectrum antibiotics, continue prophylactic penicillin</li> <li>6. Exchange transfusion or erythrocytapheresis to a Hct of 30% and Hb S ≤ 30%; remove femoral or central venous catheter as soon as possible to reduce risk of thrombosis</li> <li>7. If exchange transfusion cannot be done acutely a simple transfusion with RBC to a Hct of 30% may be done but should be followed by and exchange transfusion when available.</li> <li>8. Quantitative HbS after transfusion or at discharge</li> </ol>	<ol style="list-style-type: none"> <li>1. Clinically and neurologically stable &gt; 24 hr after transfusions</li> <li>2. Afebrile &gt; 24 hr</li> <li>3. Hematology and physical therapy follow-up organized</li> </ol>

## Priapism

Diagnosis	Monitoring	Diagnostic (if not previously obtained)	Fluids, Nutrition, General Care	Medications/ Treatments	Discharge Criteria
<p>Stuttering priapism: under 2 hrs at a time, may be recurrent Persistent: over 2 hrs continuously</p>	<ol style="list-style-type: none"> <li>1. Vital signs q 2-4 hr</li> <li>2. Record I+O, daily weight</li> <li>3. CR monitor and continuous pulse ox if receiving parenteral narcotics</li> </ol>	<ol style="list-style-type: none"> <li>1. CBC, diff, platelet count, reticulocyte count initially (compare with patient's baseline data)</li> <li>2. Urinalysis and urine culture</li> <li>3. Blood culture if febrile; consider other cultures (e.g. CSF) as indicated</li> </ol>	<ol style="list-style-type: none"> <li>1. IV fluids: 10 cc/kg over 1 hr, then IV + po = 1.25 – 1.5 x maintenance</li> <li>2. Encourage ambulation and voiding</li> <li>3. Offer warm packs or hot shower/bath if available</li> <li>4. Never use ice or cold packs</li> <li>5. Incentive spirometry - 10 breaths q 2 hr 0800-2200 and when awake if on parenteral narcotics</li> <li>6. NPO if surgical procedure planned</li> <li>7. Observe for severe headache or neurologic signs or symptoms (some suggest increased risk of stroke)</li> </ol>	<ol style="list-style-type: none"> <li>1. Urology referral urgently if priapism persists more than 2 hrs</li> <li>2. Consider pseudoephedrine &lt; 2 yr 4 mg/kg/ day split q 6 hr po; 2-5 yr 15 mg q 6 hr po; 6-12 yr 30 mg q 6 hr po, &gt;12 yr 60 mg po q 6 hr</li> <li>3. Strongly consider arranging aspiration and irrigation with epinephrine (1:1,000,000) after 2 hrs. Notify urology within 2 hrs of onset of priapism with goal of performing procedure before 6 hours. All attempts should be made to do this within 12 hrs of onset. This can be done with local and a benzodiazepine, conscious sedation or general. Repeat procedures may be required.</li> <li>4. Pain control                         <ol style="list-style-type: none"> <li>a. Ibuprofen 10 mg/kg po q 6 hr or other anti-inflammatory agent if no gastritis, ulcer or renal impairment present</li> <li>b. Morphine 0.05-0.1 mg/kg IV q 2 hr or 0.01-0.1 mg/kg/hr continuous infusion or PCA pump (max total dose) for severe pain</li> </ol> </li> <li>5. Broad-spectrum IV antibiotics if febrile</li> <li>6. If applicable, continue prophylactic penicillin (if not on broad-spectrum antibiotics) and folic acid</li> <li>7. O<sub>2</sub> by nasal cannula if needed to keep pulse ox &gt;93%.</li> <li>8. See other Clinical Care Paths for acute chest syndrome, acute anemic crisis, stroke, if present</li> </ol>	<ol style="list-style-type: none"> <li>1. Priapism resolving (complete detumescence may take 1-2 wks)</li> <li>2. Taking oral fluids well and able to take po medications (e.g. prophylactic penicillin) if applicable</li> <li>3. Adequate pain relief on oral analgesics</li> <li>4. Afebrile ≥ 24 hr</li> <li>5. Adequate oxygenation on room air</li> </ol>

Modified from Mountain States Regional Genetic Services Network, 1996

## General Anesthesia and Surgery

Pre-Op Evaluation	Pre-Op Transfusion and Pulmonary Care	Intraoperative	Post-Operatives
<ul style="list-style-type: none"> <li>• Baseline CXR, pulse ox, CBC, retic, U/A</li> <li>• Consider pulmonary function tests and/or ECHO for patients with prior history of acute chest syndrome, suspicion of chronic lung disease or decreased exercise performance</li> <li>• Coordination of peri-operative plan with Hematology, Surgery and Anesthesia</li> </ul>	<ul style="list-style-type: none"> <li>• Patient typically admitted the day before for transfusion and hydration while NPO</li> <li>• Simple transfusion targeting a Hct of 30-33% should be strongly considered for all children with Hb SS or S<math>\beta^0</math>-thalassemia prior to any procedure requiring general anesthesia</li> <li>• Surgery without pre-op transfusion in children with HbS/S and S<math>\beta^0</math>-thalassemia may be considered in selected cases non- or minimally-invasive procedures (e.g. PE tubes or MRI/MRA). Note: tonsillectomy and/or adenoidectomy is <b>not</b> considered a minor procedure. Recommendations for patients with Hb S/C and S<math>\beta^+</math>-thalassemia vary. In general, transfusion is not required for smaller procedures such as tonsillectomy and/or adenoidectomy, but transfusion is required for abdominal surgery. Due to a high baseline HCT, these patients often require exchange transfusion.</li> <li>• Use antigen-matched if available, sickle-negative, leukocyte-depleted PRBC (at a minimum RhD, Cc, Ee and Kell)</li> <li>• Practice incentive spirometry or developmentally appropriate substitute (e.g. bubbles)</li> <li>• If history of obstructive disease, start steroid inhaler 3 days before and scheduled albuterol the night before surgery</li> <li>• IV hydration 1-1.25 x maintenance while NPO before procedure. Hold while receiving blood transfusion.</li> </ul>	<ul style="list-style-type: none"> <li>• Minimum 50% O<sub>2</sub> with anesthetic agent</li> <li>• Avoid hypoxia (continuous pulse ox), hypercarbia, or hyperventilation</li> <li>• Avoid tourniquets</li> </ul>	<ul style="list-style-type: none"> <li>• O<sub>2</sub> by nasal cannula at 2 L/min and continuous pulse ox even if O<sub>2</sub> saturations are high. Continue O/N and assess the next day. Maintain saturations &gt;93%.</li> <li>• Document O<sub>2</sub> saturations on room air intermittently to screen for increasing O<sub>2</sub> need.</li> <li>• Encourage early ambulation, activity</li> <li>• IV + po 1-1.25 x maintenance. Avoid excessive hydration, which may precipitate acute chest syndrome.</li> <li>• Strict adherence incentive spirometry: 10 breaths q 2 hr while awake. Use of pain medication before this may be useful.</li> </ul>

Modified from Mountain States Regional Genetic Services Network, 1996

---

## References and Resources

### General References

- Adams, R.J., McKie, V.C., Hsu, L. et.al (1998). Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med*, 339, 5-11.
- Adams T., McKie V., Nichols F., et al. (1992). The use of transcranial ultrasonography to predict stroke in sickle cell disease. *N Engl J Med*, 326, 605-610.
- American Pain Society, Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease, 1999.
- Armstrong P.J. & Bersten A. (1986). Normeperidine toxicity. *Anesthesia and Analgesia*, 65, 536-538.
- Angling D.L., Siegel J.D., Pacini D.L. (1984). Effect of penicillin prophylaxis on nasopharyngeal colonization with streptococcus pneumonia in children with sickle cell anemia. *J Pediatr*, 104, 18-22.
- Bainbridge R., Higgs D.R., Maude G.H., et al. (1985). Clinical presentation of homozygous sickle cell disease. *J Pediatr*, 106, 881-885.
- Bakshi, S.S., Grover, R., Cabezon, E., et al. (1991). Febrile episodes in children with sickle cell disease treated on an ambulatory basis. *J Assoc Acad Minor Phys*, 2, 80-83.
- Barakat, L., Patterson, C., Daniel, L., Dampier, C. (2008). Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress. *Health and Quality of Life Outcomes*, 6 (60), p 1-9.
- Battersby, A., Huxley, HM., Knowx-Macaulay et al. (2010). Susceptibility for invasive bacterial infections in children with sickle cell disease. *Pediatric Blood & Cancer*, Sep, 55 (3), 401-6.
- Baum F.K., Dunn D.T., Maude G.H., Serjeant G.R. (1987). The painful crisis of homozygous sickle cell disease. A study of the risk factors. *Arch Intern Med*, 47, 1231-1234.
- Bellet, P., Kalinyak, K., Shukla R., et al. (1995). Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases, *NEJM*, Vol 333, No 11, 699-703.
- Bender, M.A. (updated 2009). Sickle Cell Disease in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. 1997-2009. Available at [www.genetests.org](http://www.genetests.org).
- Belgrave F.Z., Molock S.D. (1991). The role of depression in hospital admissions and emergency treatment of patients with sickle cell disease. *J Natl Med Assoc*, 83, 777-781.
- Benson, J.M., Therrell, B.L. (2010). History and current status of newborn screening for hemoglobinopathies. *Semin Perinatol*, Apr 34(2), 134-44.
- Berde C.B. In Max, M.B., Portenoy R.K., & Laska E.M. (eds.). (1991). Advances in pain research and therapy: The design of analgesic clinical trials. *Pediatric Analgesic Trials*, 18, 445-455.
- Bhatia, M., Walters, M.C. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. *Bone Marrow Transplant*, 2008. Jan;41(2):109-17.
- Brawley, O.W., Cornelius, L.J., Edwards, L.R., Gamble, V.N., Green, B.L., Inturrisi, C., James, A.H., Laraque, D., Mendez, M., Montoya, C.J., Pollock, B.H., Robinson, L., Scholnik, A.P., Schori, M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. *Ann Intern Med*, 2008 Jun 17;148(12):932-8.
- Brown A.K., Miller S.T., Agatista P. (1989). Care of infants with sickle cell disease. *Pediatrics*, 83 (5 Pt 20), 897-900.
- Buchanan G.R., Schiffman G. (1980). Antibody responses of polyvalent pneumococcal vaccine in infants with sickle cell anemia. *J Pediatr*, 96, 264-266.

- Buchanan G.R., Siegel J.D., Smith S.S., et al. (1982). Oral penicillin prophylaxis in children with impaired splenic function: A study of compliance. *Pediatrics*, 70, 926-930.
- Buchanan G.R., Smith S.J. (1986). Pneumococcal septimcemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia. *Am J Dis Child*, 140, 428-432.
- Burghardt-Fitzgerald, D. (1989). Pain behavior contracts: Effective management of adolescents in sickle cell crisis. *Journal of Pediatric Nursing*, 4, 320-324.
- Centers for Disease Control. (1989). Risk associated with human parvo-virus B19 infection. *MMWR*, 38, 81-97.
- Charache, S. (1991). Hydroxyurea as treatment for sickle cell anemia. *Hematology/Oncology Clinics of North America*, 5, 571-583.
- Chudwin D.S., Wara D.W., Matthay K.K. (1983). Increased serum opsonic activity and antibody concentration in patients with sickle cell disease after pneumococcal polysaccharide immunization. *J Pediatr*, 102, 51-54.
- Claster, S., Vichinsky, E. (2003). Managing Sickle Cell Disease. *BMJ Vol 327 15 Nov*, 1151-1155.
- Committee on Infectious Disease. (1990). Parvovirus, erythema infectiosum and pregnancy. *Pediatr*, 85, 131.
- Consensus Conference. (1987). Newborn screening for sickle cell disease and other hemoglobinopathies. *JAMA*, 258, 1205-1209.
- Cummins D., Heuschkel R., Davies S.C. (1991). Penicillin prophylaxis in children with sickle cell disease in Brent study of physician's knowledge, patient compliance. *BMJ*, 302, 989-990.
- Davies S.C., Brozovic M. (1989). The presentation, management and prophylaxis of sickle cell disease. *Blood Rev*, 3, 29.
- Day S., Brunson G., Wang W. (1992). A successful education program for parents of infants with newly diagnosed sickle cell disease. *J Pediatr Nurs*, 7, 52-57.
- DeCeulaer K., McMullen K.W., Maude G.H., et al. (1985). Pneumonia in young children with homozygous sickle cell disease: Risk and clinical features. *Eur J Pediatr*, 144, 255-258.
- Eckman J.R., Walco G.A., Erickson C.J. & Blankson V. (1994). Non-pharmacologic management of sickle syndromes. *Proceedings of the 19th Annual Meeting of the National Sickle Disease Program*, 53.
- Edmond A.M. (1985). Acute splenic sequestration in homozygous sickle cell disease: Natural history and management. *J Pediatr*, 107, 201.
- Enwonwu C.O. (1988). Nutritional support in sickle cell anemia: theoretical considerations. *J Natl Med Assoc*, 80, 139-144.
- Flanagan C. (1980). Home management of sickle cell anemia. *Pediatr Nurs*, 6, A-D.
- Falletta J.M., Woods G.M., Verter J.I., Buchanan G.R., Pegelow C.H., Iyer R.V., Miller S.T., Holbrook C.T., Kinney, T.R., Vichinsky E., et al. (1995). Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic penicillin study II. *J Pediatr*, 127, 685-690.
- Foley M.K., Inturrisi E.C. (1987). Analgesic drug therapy in cancer pain: Principles and practice. *Med Clin North Am*, 71, 207-232.
- Gaston M.H., Verter J.L., Woods G., et al. (1986). Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial. *N Engl J Med*, 314, 1593-1599.
- Gigliotti, F., Feldman, S., Wang, W.C. (1986). Serologic follow-up of children with sickle cell disease immunized with Haemophilus influenza type B conjugate vaccine during early infancy. *J Pediatr*, 118, 917-919.
- Gil, F., Sleeper, L., Weiner, S., (1995). Clinical events in the first decade in a cohort of infants with sickle cell disease, *Blood*, Vol 86, No 2 (July 15), 1995: pp 776-783.
- Gil, K., Williams, D., Thompson, R. & Kinney, T. (1991). Sickle cell disease in children and adolescents: The relation of child and parent pain coping strategies to adjustment. *Journal of Pediatric Psychology*, 16, 643-663.

- Givner L.B., Luddy R.E., Schwartz A.D. (1981). Etiology of osteomyelitis in patients with major sickle hemoglobinopathies. *J Pediatr*, 99, 411-413.
- Graff-Lonnevig V., Hedlin G., Lindfors A. (1988). Penicillin allergy: a rare pediatric condition? *Arch Dis Child*, 63, 1342-1346.
- Griffin T.C., McIntire D. and Buchanon G.R. (1994). High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. *N Engl J Med*, 330, 733-737.
- Grover R., Withers D.L. (1990). Management of acute splenic sequestration crisis in sickle cell disease. *J Assoc Acad Minority Phys*, 1, 167.
- Grover R., Shahidi S., Fisher B., et al. (1983). Current sickle cell screening program in New York City. *Am J Public Health*, 73, 249-253.
- Hales K., Barriere S. (1979). Polyvalent pneumococcal vaccine: a review. *Am J Hosp Pharm*, 36, 773-777.
- Hatton C.S.R., et al. (1985). Hepatic sequestration in sickle cell anemia. *Brit Med J*, 290, 744.
- International Rheumatic Fever Study Group. (1991). Allergic reaction to long-term benzathine penicillin prophylaxis for rheumatic fever. *Lancet*, 337, 1308-1310.
- Inturrisi C.E., Foley K.M. (1984). Narcotic analgesics in the management of pain. In M. Kuhar, G. Pasternack (Eds.), *Analgesics: Neurochemical, behavioral and clinical perspectives*. New York: Raven Press.
- Jackson S.M., Sporrer K.A., Agner S.A., Laver J.H. and Abboud M.R. (1994). Pain in children and adolescents with sickle cell anemia: a prospective study utilizing self reporting. Proceedings of the 19th Annual Meeting of the National Sickle Cell Disease Program, New York City, 86.
- Jenkins M.E., Scott R.B., Vaird R.L. (1960). Studies in sickle cell anemia: Sudden death during sickle cell anemia crisis in young children. *J Pediatr*, 56, 30.
- John A.B., Ramlal A., Jackson H., et al. (1984). Prevention of pneumococcal infection in children with homozygous sickle cell disease. *BMJ*, 288, 1567-1570.
- Kaplan E.C., Berrios X., Speth J., et al. (1989). Pharmacokinetics of benzathine penicillin serum levels during the 29 days after IM injection of 1.2 IU. *J Pediatr*, 115, 146-150.
- Karko R.F., Foley K.M., Grabinsky P.Y., et al. (1983). Central nervous system excitatory effects of meperidine in cancer patients. *Ann Neurol*, 13, 180-185.
- Kawchak, D., Schall, J., Zemel, B, Ohene-Frempong, K. et al. (2007). Adequacy of dietary intake declines with age in children with sickle cell disease. *J Am Diet Assoc*, May 107 (5), 843-8.
- Kim, H.C., Alavi, A., Russel, M., et al. (1989). Differentiation of bone and bone marrow in infants from osteomyelitis in sickle cell diseases. *Clin Nucl Med*, 141, 249-254.
- Kinney, T.R., et al. (1990). Long-term management of splenic sequestration in children with sickle cell disease. *J Pediatr*, 117, 194.
- Kuisel L., Shearer J., Jackson S.M., et al. (1994). Home pain management in adolescents with severe sickle cell disease. Proceedings of the 19th Annual Meeting of the National Sickle Cell Disease Program, 104.
- Lee, MT., Piomelli, S., Granger, S. et al. (2006). Stroke Prevention Trial in Sickle Cell Anemia (STOP): Extended follow-up and final results. *Blood*, Aug 1, 108 (3), 847-52.
- Leikin S.L., Gallagher D., Kinney T.R. (1989). Mortality in children and adolescents with sickle cell disease. *Pediatrics*, 84, 500-508.
- Listernick R., Frisone L., Silverman B.L. (1992). Delayed diagnosis of infection with abnormal neonatal screens. *JAMA*, 267, 1095-1099.
- Lobel J.S., Cameron B.F., Johnson E., et al. (1989). Value of screening umbilical cord blood for hemoglobinopathy. *Pediatrics*, 83 (5 Pt 2), 823-826.
- Marcinak J.F., Frank A.L., Labotka R.L., et al. (1991). Haemophilus influenza type B vaccine in children with sickle cell disease: Antibody persistence after vaccination at age 1 1/2 to 6 years. *Pediatr Infect Dis J*, 10, 157-159.

- McClish, D.K., Smith, W.R., Dahman, B.A., et al. (2009). Pain site frequency and location in sickle cell disease: the PiSCES Project. *Pain, Sep*; 145 (1-2), 246-51.
- McIntosh S., Rooks Y., Richey A.K., et al. (1980). Fever in young children with sickle cell disease. *J Pediatr*, 96, 199-204.
- Melzer-Lange, M.D., Walsh-Kelly, C.M., Lea, G., Hillery, C.A., Scott, J.P. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. *Pediatr Emerg Care*, 2004 Jan;20(1):2-4.
- Miller S.T., Stilerman T.V., Rao S.P., et al. (1990). Newborn screening for sickle cell disease: When is an infant lost to follow-up? *Am J Dis Child*, 144, 1343-1345.
- National Institute of Health, (2002). The Management of Sickle Cell Disease. National Heart, Lung and Blood Institute Publication No. 02-2117, Fourth Edition. [www.nhlbi.nih.gov/health/prof/blood/sickle/sc\\_mngt.pdf](http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf).
- Ndumbe P.M., Nyouma E. (1990). Transmission of hepatitis B virus by blood transfusion in Yaounde, Cameroon. *BMJ*, 301, 523-524.
- Nielsen, K.T., Bender, M.A. 2011. Hemoglobinopathies. In: *Pediatric Critical Care*, 4th Edition by Bradley P. Fuhrman and Jerry J. Zimmerman. Elsevier Press. Chapter 84, pp 1191-1206.
- Nussbaum, R.L., Powell, C., Graham, H.L., et al. (1984). Newborn screening for sickling hemoglobinopathies. Houston, 1976 to 1980. *Am J Dis Child*, 138, 44-48.
- O'Brien, R.T., McIntosh, S., Aspnes, G.T., et al. (1976). Prospective study of sickle cell anemia in infancy. *J Pediatr*, 89, 205-210.
- Ohene-Frempong, K. (1991). Stroke in sickle cell disease: Demographic, clinical and therapeutic considerations. *Semin Hematol*, 28, 213-219.
- Overturf, G.D. (1982). Pneumococcal vaccination: Update and evaluation. *Prog Clin Biol Res*, 98, 59-71.
- Overturf, G.D., Powars, D., Baraff, L.J. (1977). Bacterial meningitis and septicemia in sickle cell disease. *Am J Dis Child*, 131, 784-787.
- Pattison Jr., et al. (1981). Parvovirus infections and hypoplastic crisis in sickle cell anemia. *Lancet*, 1,644.
- Pavlakakis S.G., Prohovnik I., Piomelli S., et al. (1989). Neurologic complications of sickle cell disease [Retraction of Barnes LA]. *Adv Pediatr*, 36, 247-276.
- Pearson H.A. (1986). Sickle cell disease: Diagnosis and management in infants and children. *Pediatr Rev*, 9, 121.
- Pearson H.A., Cobb W.T. (1964). Folic acid studies in sickle cell anemia. *J Lab Clin Med*, 64, 913-921.
- Pegelow C.H., Armstrong F.D., Light S., et al. (1991). Experience with the use of prophylactic penicillin in children with sickle cell anemia. *J Pediatr*, 118, 736-738.
- Pegelow C. (1992). Survey of pain management therapy provided for children with sickle cell disease. *Clinical Pediatrics*, 31, 211-214.
- Platt, A., Beyer, J., Kinney, T., West, M. (1995). Recommendations for assessing sickle cell pain. *Proceedings of the 19th Annual Meeting of the National Sickle Cell Disease Program*, 145.
- Platt, O. (1994). Easing the suffering caused by sickle cell disease. *New Engl J Med*, 330, 783-784.
- Platt, O.S., Brambilla, D.J., Rosse, W.F., et al. (1994). Mortality in sickle cell disease: life expectancy and risk factors for early death. *N Engl J Med*, 330(23) 1639-1644.
- Platt, O.S., Thorington, B.D., Brambilla, D.J., et al. Pain in sickle cell disease. Rates and risk factors. *N Engl J Med*, 1991;325:11-16.
- Porter, C., Villarruel, A. (1992). Socialization and caring for hospitalized African-American and Mexican-American children. *Issues in Comprehensive Pediatric Nursing*, 14, 1-16.
- Porter, J., Jick II. (1980). Addiction is rare in patients treated with narcotics. *New Engl J Med*, 302, 123.

- Powars, D.R. (1975). Natural history of sickle cell disease: First 10 years. *Semin Hematol*, 12, 267-285.
- Powars, D.R., Overturf, G., Weiss, J., et al. (1981). Pneumococcal septicemia in children with sickle cell anemia: Changing trend of survival. *JAMA*, 245, 1839-1842.
- Rabb, et al. (1983). A trial of folate supplementation in children with homozygous sickle cell disease. *Br J Haematol*, 54, 589.
- Rao S., Pang. (1982). Transfusion therapy for subacute splenic sequestration in sickle cell anemia. *Blood*, 60 (suppl), 489.
- Rodgers G.P., Dover G.J., Noguchi C.T., et al. (1990). Hematologic responses of patients with sickle cell disease to hydroxyurea. *New Engl J Med*, 322, 1037-1045.
- Rogers D.W., et al. (1978). Early deaths in Jamaican children with sickle cell disease. *Br J Med*, 1, 1515.
- Rogers Z.R., Morrison R.A., Vedro D.A., et al. (1990). Outpatient management of febrile illness in infants and young children with sickle cell anemia. *J Pediatr*, 117, 736-739.
- Rowley P.T., Huntzinger D.J. (1983). Newborn sickle cell screening: Benefits and burdens realized. *Am J Dis Child*, 137, 341-345.
- St. Jude Children's Research Hospital, Department of Hematology-Oncology: Chesney P.J., Day S.W., Eguiguren J.M., Fairclough D.L., Flynn P.M., Harris S., Rodman J.H., Smith R., Wang W.C., & Williams J.A. (1993). A randomized study of outpatient treatment with deftriaxone for selected febrile children with sickle cell disease. *New Engl J Med*, 329, 472-476.
- Sandler D.P., Smith J.C., Weinberg C.R., et al. (1989). Analgesic use and chronic renal disease. *New Engl J Med*, 320, 123-138.
- Schechter N., Berrien F. & Katz S. (1988). The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: A preliminary report. *Journal of Pain and Symptom Management*, 3, 1029-1045.
- Schubert T.T. (1986). Hepatobiliary system in sickle disease. *Gastroenterology*, 90, 2013.
- Seeler R.A., Metzger W., Mufson A. (1972). *Ciplococcus pneumoniae* infections in children with sickle cell anemia. *Am J Dis Child*, 123, 8-10.
- Seeler R.A., Shwiaki M.Z. (1972). Acute splenic sequestration crisis (ASSC) in young children with sickle cell anemia: Clinical observations in 20 episodes in 14 children. *Clin Pediatr*, 11, 701-704.
- Serjeant G.R. (1985). Treatment of sickle cell disease in early childhood in Jamaica. *Am J Pediatr Hematol Oncol*, 7, 235-239.
- Shapiro B. (1989). The management of pain in sickle cell disease. *Pediatric Clinics of North America*, 36, 1029-1045.
- Shaprior B. (1991). Sickle cell disease-related pain. *IASP Newsletter*, January-February, 2-4.
- Sharpe J., Brown R., Thompson N., Buchanan I. and Eckman J. (1994). Predictors of coping with pain in mothers and their children with sickle cell disease. *Proceedings of the 19th Annual Meeting of the National Sickle Cell Disease Program*, 174.
- Sheehy T.W. (1970). Sickle cell hepatopathy. *So Med J*, 70, 533.
- Sills R. (1987). Splenic function: Physiology and splenic hypofunction. *Crit Rev Oncol Hematol*, 7, 1-36.
- Smith J. (1993). Management of sickle cell disease: Progress during the past 10 years. *American Journal of Pediatric Hematology/Oncology*, 5, 360-365.
- Smith-Whitely, K., Zhao, H., Hodinka, R., et al. (2004). Epidemiology of human parvovirus B19 in children with sickle cell disease. *Blood*, Vol 103 (2) 422-27.
- Spirer A. (1980). The role of the spleen in immunity and infection. *Adv Pediatr*, 27, 55-88.
- Thurn J. (1988). Human parvovirus B19: Historical and clinical review. *Rev Inf Dis*, 10, 1005-1011.
- Todd, K., Green, C., Bonham, V., et al. (2006). Sickle Cell Disease Related Pain: Crisis and Conflict. *The Journal of Pain*, Vol 7, No 7 (July), 2453-458.

Topley J.M., Rogers D.W., Stevens M.C., et al. (1981). Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. *Arch Dis Child*, 56, 765-769.

Topley J.M., et al. (1981). Acute splenic sequestration crisis in your children with sickle cell anemia. *Arch Dis Child*, 56, 765.

University of Texas Southwestern Medical Center, Department of Pediatrics: Buchanan G.R., Morrison R.A., Rogers Z.R. & Vedro D.A., Dallas TX 75235-9063. (1990). Outpatient management of febrile illness in infants and young children with sickle cell anemia. *Journal of Pediatrics*, 117, 736-739.

U.S. Department of Health and Human Services, National Institute of Health (2002). The management of sickle cell disease. NIH publication no. 02-0117. [www.nhlbi.nih.gov/health/prof/blood/sickle/sc\\_mngt.pdf](http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf)

Van Beers, E., van Tuijn, C., Nieuwkerk, P., et al. (2007). Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. *American Journal of Hematology*, Vol 82 (11), pg 955-960.

Vermeylen C., Cornu G., Philippe M., et al. (1991). Bone marrow transplantation in sickle cell anemia. *Arch Dis Child*, 66, 1195-1198.

Vichinsky E., et al. (1981). The diagnosis of iron deficiency anemia in sickle cell disease. *Blood*, 58, 963.

Vichinsky E., Hurst D., Earles A., et al. (1988). Newborn screening for sickle cell disease: Effect on mortality. *Pediatrics*, 81, 749-755.

Vishinsky E., Lubin B.H. (1987). Suggested guidelines for the treatment of children with sickle cell anemia. *Hematol Oncol Clin North Am*, 1, 483-501.

Vinchinsky, E., Neumayr L., Earles, A., et al. (2000). Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease, *N Engl J Med*, 342:1855-65.

Vinchinsky, E., Neumayr, L., Gold, J., et al. (2010). Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *JAMA*, May 12, 2010, Vol 303, No 18, 1823-1831.

Vichinsky, E.P., Styles, L.A., Colangelo, L.H., Wright, E.C., Castro, O., Nickerson, B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. *Blood*. 1997 Mar 1;89(5):1787-92.

Warren N.S., Carter T.P., Humbert J.R., et al. (1982). Newborn screening for hemoglobinopathies in New York state: Experience of physicians and parents of affected children. *J Pediatr*, 100, 373-377.

Webb D.K., Serjeant G.R. (1989). Systemic salmonella infection in sickle cell anemia. *Ann Trop Pediatr*, 9, 169-172.

White P.F. (1988). Use of patient-controlled analgesia for management of acute pain. *JAMA*, 259, 243-247.

Whitten C.F. (1989). Newborn screening for sickle cell disease and other hemoglobinopathies: Perspective from the National Association for Sickle Cell Disease. *Pediatrics*, 83 (5 Pt 2), 906-7.

Wilson, R., Krishnamurti, L., Kamat, D. (2003). Management of Sickle Cell Disease in Primary Care. *Clin Pediatr*. 42:753-761.

Wright L., Brown A., Davidson-Mundt A. (1992). Newborn screening: The miracle and the challenge. *J Pediatr Nurs*, 7, 26-42.

Zarkowsky H.S., Gallagher D., Gill F.M., et al. Bacteremia in sickle hemoglobinopathies. *J Pediatr*, 1986.

**RESOURCES**

***Patient Education and Information on Sickle Cell***

**All You Ever Wanted to Know about Sickle Cell Trait.** California Department of Public Health, 2006. [www.cdph.ca.gov/programs/nbs/Documents/NBSAllUWanted2KnowSickleCellTrait2006.pdf](http://www.cdph.ca.gov/programs/nbs/Documents/NBSAllUWanted2KnowSickleCellTrait2006.pdf)

**Family Connection – Hemoglobin C Trait.**

New York State Department of Health. [www.wadsworth.org/newborn/hemotrait/index.htm](http://www.wadsworth.org/newborn/hemotrait/index.htm)

**Kids’ Health.** Information for parents, teens and children on sickle cell. [http://kidshealth.org/parent/medical/heart/sickle\\_cell\\_anemia.html#](http://kidshealth.org/parent/medical/heart/sickle_cell_anemia.html#)

**The Management of Sickle Cell disease.** U.S. Department of Health and Human Services, National Institute of Health. [www.nhlbi.nih.gov/health/prof/blood/sickle/sc\\_mngt.pdf](http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf)

**Parents’ Handbook for Sickle Cell Disease Part**

**I: Birth – 6 years.** California Department of Public Health. [www.cdph.ca.gov/programs/nbs/Documents/NBS-SCParentsHandbookPart1.pdf](http://www.cdph.ca.gov/programs/nbs/Documents/NBS-SCParentsHandbookPart1.pdf)

**Parents’ Handbook for Sickle Cell Disease Part II: 6-18 years of age.** State of California Department of Public Health, Genetic Disease Screening Program, 2008. [www.cdph.ca.gov/programs/nbs/Documents/NBS-ParentHandbook4SCDx2\\_Aug04.pdf](http://www.cdph.ca.gov/programs/nbs/Documents/NBS-ParentHandbook4SCDx2_Aug04.pdf)

**Sickle Cell Information Center.** <http://scinfo.org>

**Texas Department of Health, Newborn Screening Program.** Information on sickle cell trait, sickle β-thalassemia, hemoglobin C disease, pain in children and various complications. [www.dshs.state.tx.us/newborn/sickle.shtm](http://www.dshs.state.tx.us/newborn/sickle.shtm)

**Thalassemia Information Sheet.** March of Dimes. [www.marchofdimes.com/baby/birthdefects\\_thalassemia.html](http://www.marchofdimes.com/baby/birthdefects_thalassemia.html)

**Things to Know About Sickle Cell Trait.** Texas State Department of Health. [www.dshs.state.tx.us/newborn/sctrain.shtm](http://www.dshs.state.tx.us/newborn/sctrain.shtm)

**Newborn Screening Information**

**What Should I know About Newborn Screening?** Washington State Department of Health. [www.doh.wa.gov/ehsphl/phl/newborn/parentspage.htm](http://www.doh.wa.gov/ehsphl/phl/newborn/parentspage.htm)

**Regional and National Foundations**

**American Sickle Cell Anemia Association.** [www.ascaa.org](http://www.ascaa.org)

**National Heart, Lung, and Blood Institute.** [www.nhlbi.nih.gov/new/sicklecell.htm](http://www.nhlbi.nih.gov/new/sicklecell.htm)

**Northwest Sickle Cell Collaborative.** Resources, information, support and community events. For families, kids and health care professionals. [www.nwsicklecell.org/](http://www.nwsicklecell.org/)

**Parent to Parent (P2P).** Support programs of Washington State that provides emotional support and information to families of children with special needs and/or disabilities. [www.arcwa.org/parent\\_to\\_parent.htm](http://www.arcwa.org/parent_to_parent.htm)

**Sickle Cell Disease Association of America, Inc.** [www.sicklecelldisease.org](http://www.sicklecelldisease.org)

**Starbright Foundation.** Starlight Children’s Foundation has been dedicated to improving the quality of life for children with chronic and life-threatening illnesses and life-altering injuries by providing entertainment, education and family activities that help them cope with the pain, fear and isolation of prolonged illness. [www.starbright.org/Default.aspx?id=2147483750&terms=sickle+cell](http://www.starbright.org/Default.aspx?id=2147483750&terms=sickle+cell)

*Funded by the Washington State Department of Health Children  
with Special Health Care Needs Program*

© 2002, 2006, 2012 Seattle Children's Hospital, Seattle, Washington.  
*All rights reserved.*



Center for Children  
with Special Needs  
[www.cshcn.org](http://www.cshcn.org)